Package | Version | Identity | Name/Title | Status | Date |
---|
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2028  | Bartonellosis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2029  | Bartonellosis (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2030  | Bartonella henselae infection (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2031  | Bartonella quintana infection (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2032  | Bartonella bacilliformis infection (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2033  | Bartonella henselae infection (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2034  | Bartonella quintana infection (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2036  | Bartonella henselae (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2037  | Bartonella quintana (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2038  | Bartonella bacilliformis (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2039  | Bartonella quintana infection (Tests for Bartonella quintana Nucleic Acid) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.204  | Giardiasis (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2040  | Bartonella quintana infection (Tests for Bartonella quintana IgM Antibody in a clinical specimen by any method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2041  | Bartonella quintana infection (Tests for Bartonella quintana IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2042  | Bartonella henselae infection (Tests for Bartonella henselae Nucleic Acid) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2043  | Bartonella henselae infection (Tests for Bartonella henselae IgM Antibody in a clinical specimen by any method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2044  | Bartonella henselae infection (Tests for Bartonella henselae IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2045  | Bartonella bacilliformis infection (Tests for Bartonella bacilliformis IgM Antibody in a clinical specimen by any method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2046  | Bartonella bacilliformis infection (Tests for Bartonella bacilliformis IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2047  | Bartonellosis (Tests for Bartonella spp. Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2048  | Bartonellosis (Tests for Bartonella spp. IgM Antibody in a clinical specimen by any method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2049  | Bartonella spp. (Tests by Microscopic Observation) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2050  | Bartonellosis (Tests for Bartonella spp. by Culture and Identification Method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2051  | Bartonellosis (Tests for Bartonella spp. IgG or Total Antibody in a clinical specimen by any method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2052  | Echinococcosis (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2053  | Echinococcosis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2054  | Cystic Echinococcosis (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2055  | Cystic Echinococcosis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2056  | Alveolar Echinococcosis (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2057  | Alveolar Echinococcosis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2058  | Echinococcosis (Tests for Echinococcus species Antibody) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2059  | Echinococcus species (Tests by Microscopic Observation) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2060  | Echinococcosis (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2061  | Genital Warts (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2062  | Pseudomembrane [Nose, pharynx, tonsils, or larynx] (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2063  | Genital Warts (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2064  | Diphyllobothriasis (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2065  | Diphyllobothriasis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2066  | Diphyllobothriasis (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2067  | Nontuberculous Mycobacteria Infection, Pulmonary (Tests for Mycobacterium species Nucleic Acid in a Pulmonary Specimen) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2068  | Angiostrongyliasis (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2069  | Pelvic Inflammatory Disease (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2070  | Pelvic Inflammatory Disease [nonGC and nonCT] (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2071  | Pelvic Inflammatory Disease [Unspecified] (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2072  | Pelvic Inflammatory Disease (Disorders) (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2073  | Pelvic Inflammatory Disease [nonGC and nonCT] (Disorders) (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2074  | Pelvic Inflammatory Disease [Unspecified] (Disorders) (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2075  | Lower Abdominal Tenderness (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2076  | Lower Abdominal Tenderness (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2077  | Tenderness with motion of the cervix (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2078  | Adnexal Tenderness (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2079  | Uterine Tenderness (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2080  | Leukocytosis (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2081  | Leukocytosis (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2082  | Purulent material in the peritoneal cavity (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2083  | Pelvic Abscess (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2084  | Pelvic Abscess (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2085  | Leukocytes [Concentration] (Tests in Blood by Any Method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2087  | Nongonococcal Urethritis (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2088  | Nongonococcal Urethritis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2089  | Urethritis (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2090  | Urethritis (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2091  | Urethral discharge (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2092  | Urethral discharge (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2093  | Dysuria (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2094  | Dysuria (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2095  | Gonorrhea (Tests for Neisseria gonorrhoeae Antigen) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2096  | Cyanobacteria and Cyanotoxin Poisoning (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2098  | Rhinitis (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2100  | Rhinitis (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2101  | Pleuritis (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2102  | Pleuritis (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2103  | Gamma Glutamyl Transferase in Serum (Tests for Gamma Glutamyl Transferase in Serum) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2105  | Methemoglobinemia (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2106  | Methemoglobinemia [Non Congenital] (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2107  | Methemoglobinemia (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2108  | Methemoglobinemia [Non Congenital] (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2109  | Methemoglobinemia (Tests for Methemoglobin in Blood [Quantitative]) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2110  | Anencephaly (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2111  | Anencephaly (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2112  | Fetal Anencephaly (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2113  | Fetal Anencephaly (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2114  | Cleft Lip Alone (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2115  | Cleft Lip Alone (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2116  | Fetal Cleft Lip (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2117  | Cleft Palate Alone (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2118  | Cleft Palate Alone (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2119  | Cleft Lip with Cleft Palate (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2120  | Cleft Lip with Cleft Palate (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2121  | Fetal Spina Bifida (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2122  | Spina Bifida (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2123  | Spina Bifida (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2124  | Down Syndrome (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2125  | Down Syndrome (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2126  | Fetal Down Syndrome (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2127  | Fetal Down Syndrome (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2128  | Down Syndrome (Tests for Trisomy 21 Chromosomal Anomaly) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2129  | Bacteremia (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2130  | Bacteremia (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2131  | Gastroschisis (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2132  | Gastroschisis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2133  | Fatal Familial Insomnia (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2134  | Fatal Familial Insomnia (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2135  | Gerstmann Straussler Scheinker Syndrome (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2136  | Gerstmann Straussler Scheinker Syndrome (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2137  | Prion Disease (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2138  | Prion Disease (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2139  | Prion Disease (Tests for Abnormal PRNP Gene Variant) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2140  | Phenylketonuria (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2141  | Phenylketonuria (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2142  | Linezolid (RXNORM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2143  | Tuberculosis (Pretomanid) (RXNORM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2144  | Tuberculosis (Bedaquiline) (RXNORM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2145  | Tuberculosis [Suspected] (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2146  | Congenital Rubella Syndrome [Suspected] (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2147  | Limb Reduction (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2148  | Limb Reduction (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2149  | NU_Influenza (Test Panels for Novel influenza A virus Nucleic Acid) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2150  | Congenital Hearing Loss (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2151  | Congenital Hearing Loss (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2152  | Naegleria fowleri PAM (Test Panels for Naegleria fowleri Nucleic Acid) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2153  | Primary Congenital Hypothyroidism (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2154  | Congenital Hypothyroidism [Unspecified] (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2155  | Congenital Hypothyroidism [Unspecified] (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2156  | Thyroid_stimulating hormone (TSH) [Quantitative] (Tests in serum or plasma by any method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2157  | Mpox (Combination Tests that include mpox virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2158  | Orthopox (Combination Tests that include Orthopoxvirus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2159  | Mpox (Test Panels for mpox virus Nucleic Acid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.216  | Pertussis (Tests for Bordetella pertussis Antibody [Excluding Pertussis Toxin Antibody]) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2160  | Orthopox (Test Panels for orthopoxvirus Nucleic Acid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2161  | COVID_19 (Combination Tests that include SARS_CoV_2 Nucleic Acid) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2163  | Dengue Virus Infection [Suspected] (Disorders) (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2164  | Mumps [Suspected] (Disorders) (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2165  | Pertussis [Suspected] (Disorders) (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2166  | Hantavirus Infection (Test Panels for Hantavirus IgM IgG Total Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2167  | Organisms (Tests in Cerebrospinal Fluid by Culture and Identification Method) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2168  | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis in Unspecified Specimen by Culture and Identification) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2169  | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis in Cerebrospinal Fluid by Culture and Identification) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2170  | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis in Unspecified Specimen by Culture and Identification) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2171  | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis in Unspecified Specimen by Culture and Identification) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2172  | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2173  | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2174  | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2175  | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Nucleic Acid in Unspecified Specimen) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2176  | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Antigen in Unspecified Specimen) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2177  | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Antigen in Unspecified Specimen) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2178  | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Antigen in Unspecified Specimen) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2179  | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Antigen in Unspecified Specimen) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.218  | Listeriosis (Disorders) (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2180  | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis in Unspecified Specimen by Microscopic Observation) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2181  | Organisms (Tests by Microscopic Observation in Cerebrospinal Fluid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2183  | Bacteria [Causing Encephalitis] (Tests for Bacteria Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2187  | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2188  | Fungi [Causing Encephalitis] (Tests for Fungi Causing Encephalitis Antigen in Cerebrospinal Fluid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2189  | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis in Cerebrospinal Fluid by Microscopic Observation) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2190  | Parasites [Causing Encephalitis] (Tests for Parasites Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2192  | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Nucleic Acid in Cerebrospinal Fluid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2193  | Viruses [Causing Encephalitis] (Tests for Viruses Causing Encephalitis Antigen in Cerebrospinal Fluid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2194  | Organisms (Combination Tests by Culture and Identification) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2195  | Organisms (Combination Tests for Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2196  | Lung Tissue (Specimen Type) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2197  | Granuloma [Unspecified] (Finding by Microscopic Observation in Lab Results) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2198  | Anaplasmosis (Disorders) (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2199  | NU_Organisms (Tests in Specimen from Wound by Culture and Identification Method | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2200  | Organisms (Tests by Animal Inoculation Method) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2201  | Agricultural Chemical Poisoning [Unspecified Chemical] (Disorders) (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2202  | Abnormal Lung Sounds (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2203  | Abnormal Lung Sounds (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2204  | Anemia [Unspecified Cause] (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2205  | Anemia [Unspecified Cause] (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2206  | Creatinine (Tests in Serum by Any Method) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2207  | Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Tests by Microscopic Observation in Unspecified Specimen) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2208  | Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Tests by Microscopic Observation in Blood) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2209  | Microangiopathic Changes (Schistocytes, Burr cells, or Helmet cells) (Organism or Substance in Lab Results) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2210  | Histopathology or Cytopathology Tests by Microscopic Observation | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2211  | Ehrlichiosis (Tests for Ehrlichia species IgG Antibody) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2212  | Invasive Cronobacter Infection (Organism or Substance in Lab Results) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2213  | Invasive Cronobacter Infection (Tests for Cronobacter species by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2214  | Necrotizing Enterocolitis (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2215  | Necrotizing Enterocolitis (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2216  | Abscess [Brain] (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2217  | Abscess [Brain] (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2218  | Urinary Tract Infection (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2219  | Urinary Tract Infection (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2220  | Amniotic Fluid (Specimen Type) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2221  | Congenital Cytomegalovirus (Organism or Substance in Lab Results) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2222  | Organisms (Tests in Amniotic Fluid by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2223  | Congenital Cytomegalovirus (Tests for CMV Antigen by Immunohistochemical Stain) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2224  | Congenital Cytomegalovirus (Tests for CMV Antigen in Tissue by Immunohistochemical Stain) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2225  | Congenital Cytomegalovirus (Tests for CMV in Amniotic Fluid by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2226  | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid in Amniotic Fluid by NAAT) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2227  | Congenital Cytomegalovirus (Tests for CMV Antigen in Whole Blood) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2228  | Congenital Cytomegalovirus (Tests for CMV Antigen) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2229  | Congenital Cytomegalovirus (Tests for CMV by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2230  | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid by NAAT) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2231  | Congenital Cytomegalovirus Infection (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2232  | Congenital Cytomegalovirus Infection (Disorders) (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2233  | Cytomegalovirus Disease (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2234  | Cytomegalovirus Disease (Disorders) (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2235  | Toxoplasmosis (Tests for Toxoplasma gondii Antigen by Immunohistochemical Stain) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2236  | Toxoplasmosis (Tests for Toxoplasma gondii Antigen in Tissue by Immunohistochemical Stain) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2237  | Toxoplasmosis (Tests for Toxoplasma gondii IgG IgM IgA or IgE Antibody) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2238  | Toxoplasmosis (Tests for Toxoplasma gondii IgG IgM IgA or IgE Antibody in Blood) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2239  | Toxoplasmosis (Tests for Toxoplasma gondii IgG or IgM Antibody) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2240  | Toxoplasmosis (Tests for Toxoplasma gondii IgG or IgM Antibody in Cerebrospinal Fluid) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2241  | Stillbirth (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2242  | Stillbirth (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2243  | Zika Virus Disease (Tests for Zika virus IgM Antibody in Blood or CSF) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2244  | Candida species (Tests by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2245  | Organisms (Tests in Extrapulmonary Specimen by Culture and Identification) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2246  | Organisms (Tests for Nucleic Acid in Extrapulmonary Specimen) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2247  | Extrapulmonary [NTM] (Specimen Type) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2248  | Plasmodium species (Tests by Microscopic Observation) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2249  | Baylisascariasis (Tests for Baylisascaris species Antibody in Serum or CSF) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2250  | Lower Respiratory [Excluding Sputum] (Specimen Type) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2251  | Organisms (Tests in Sputum Specimen by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2252  | Organisms (Tests in Lower Respiratory Specimen [Excluding Sputum] by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2253  | Organisms (Tests for Nucleic Acid in Lower Respiratory Specimen [Including Sputum]Â ) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2254  | Nontuberculous Mycobacteria Infection, Pulmonary (Tests for Mycobacterium species in Lower Respiratory Specimen [Excluding Sputum] by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2255  | Carbapenem Resistant Bacterial Infection [Carbapenemase Producing] (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2256  | CP_CRE (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2257  | Organisms (Tests in Stool by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2258  | Loss of Consciousness (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2259  | Neonatal Abstinence Syndrome (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.226  | Lyme Disease (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2260  | Neonatal Abstinence Syndrome (Disorders) (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2261  | High Pitched Cry (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2262  | Inability to Console (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2263  | Inability to Console (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2264  | Hypertonia (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2265  | Hypertonia (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2266  | Tremors (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2267  | Tremors (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2268  | Myoclonus (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2269  | Myoclonus (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.227  | Lyme Disease (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2270  | Poor Sleep (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2271  | Poor Sleep (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2272  | Alterations in Feeding (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2273  | Alterations in Feeding (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2274  | Excoriation (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2275  | Excoriation (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2276  | Sneezing (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2277  | Sneezing (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2278  | Nasal Congestion (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2279  | Nasal Congestion (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2280  | Yawning (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2281  | Cutaneous Mottling (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2282  | Sweating (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2283  | Sweating (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2284  | Feeding Intolerance (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2285  | Feeding Intolerance (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2286  | Respiratory Distress or Nasal Flaring (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2287  | Respiratory Distress or Nasal Flaring (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2288  | In Utero Exposure to Opioids, Benzodiazepines, or Barbiturates (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2289  | In Utero Substance Exposure (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2290  | In Utero Substance Exposure (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2291  | Childbirth (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2292  | Childbirth (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2293  | Opioids, Benzodiazepines, or Barbiturates (Tests by Any Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2294  | NonOpioid, NonBenzodiazepine, and NonBarbiturate Substances (Tests by Any Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2295  | Opioids, Benzodiazepines, or Barbiturates (Organism or Substance in Lab Results) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2296  | NonOpioid, NonBenzodiazepine, or NonBarbiturate Substances (Organism or Substance in Lab Results) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2297  | Exposure or suspected exposure to harmful algae or algae toxins (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2298  | Exposure or suspected exposure to harmful algae or algae toxins (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2299  | Group A Streptococcus (Tests for Group A Strep in Specimen from Normally Sterile Site by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2300  | Babesia species (Tests by Microscopic Observation) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2301  | Babesia species (Tests by Microscopic Observation in Blood by Giemsa, Wright, or Wright_Giemsa Stain) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2302  | Babesia species (Tests by Microscopic Observation by Giemsa, Wright, or Wright_Giemsa Stain) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2303  | Organisms (Tests by Microscopic Observation in Blood by Giemsa, Wright, or Wright_Giemsa Stain) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2304  | Organisms (Tests by Microscopic Observation by Giemsa, Wright, or Wright_Giemsa Stain) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2305  | Gram_negative Diplococcus (Organism or Substance in Lab Results) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2306  | Pertussis (Test Panels for Bordetella pertussis and Bordetella parapertussis Culture and Identification Method) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2307  | D_Transposition of the Great Arteries (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2308  | L_Transposition of the Great Arteries (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2309  | Transposition of the Great Arteries [Unspecified] (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2310  | Transposition of the Great Arteries [Unspecified] (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2311  | Interrupted Aortic Arch (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2312  | Interrupted Aortic Arch (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2313  | Coarctation of the Aorta (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2314  | Coarctation of the Aorta (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2315  | Ebstein Anomaly (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2316  | Ebstein Anomaly (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2317  | Pulmonary valve atresia (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2318  | Pulmonary valve atresia (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2319  | Pulmonary valve stenosis (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2320  | Pulmonary valve stenosis (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2321  | Fetal Pulmonary valve stenosis (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2322  | Double Outlet Right Ventricle (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2323  | Double Outlet Right Ventricle (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2324  | Hypoplastic left heart syndrome (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2325  | Hypoplastic left heart syndrome (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2326  | Single Ventricle (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2327  | Single Ventricle (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2328  | Tetralogy of Fallot (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2329  | Tetralogy of Fallot (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2330  | Truncus Arteriosus (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2331  | Truncus Arteriosus (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2332  | Atrioventricular septal defect (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2333  | Atrioventricular septal defect (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2334  | Total Anomalous Pulmonary Venous Connection (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2335  | Total Anomalous Pulmonary Venous Connection (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2336  | Tricuspid valve atresia (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2337  | Tricuspid valve atresia (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2338  | Tricuspid valve stenosis (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2339  | Tricuspid valve stenosis (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2340  | Fetal Tricuspid valve stenosis (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2341  | Exposure to Measles (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2342  | Increased Risk for Exposure to Measles (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2343  | Giardiasis (Tests by Microscopic Observation) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2344  | Diphtheria (Tests for Diphtheria Toxin Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2345  | Lead in Blood (Tests for Lead in Venous Blood) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2346  | Lead in Blood (Tests for Lead in Capillary Blood) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2347  | Opioid Overdose and Poisoning (Test Panels for Opioids) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2348  | Rubella (Test Panels for rubella virus IgM Antibody) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2349  | Consistent with Tuberculosis (Finding in Chest Xray Imaging Results) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2350  | Acute Viral Hepatitis (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2351  | Shigellosis (Combination Tests that include Shigella species by Culture and Identification) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2352  | Acid Fast Bacilli (Tests by Microscopic Observation by Fite Stain) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2353  | Acid Fast Bacilli (Tests by Microscopic Observation in Skin or Unspecified Tissue by Fite Stain) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2354  | Organisms (Tests by Microscopic Observation by Unspecified Acid Fast Stain) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2355  | Organisms (Tests by Microscopic Observation by Unspecified Acid Fast Stain in Skin) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2356  | Skin (Specimen Type) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2357  | Organisms (Tests by Microscopic Observation in Skin) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2358  | Unspecified Tissue (Specimen Type) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2359  | Organisms (Tests by Microscopic Observation in Unspecified Tissue) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2360  | S. Paratyphi Infection (Tests for S. Paratyphi by Culture and Identification Method) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2361  | S. Paratyphi Infection (Tests for S. Paratyphi Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2362  | Tuberculosis (Ethambutol) (RXNORM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2363  | Tuberculosis (Isoniazid [INH]) (RXNORM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2364  | Tuberculosis (Pyrazinamide [PZA]) (RXNORM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2365  | Tuberculosis (Rifabutin) (RXNORM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2366  | Tuberculosis (Rifampin) (RXNORM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2367  | Tuberculosis (Rifapentine) (RXNORM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2368  | Perinatal Hepatitis B (Maternal Hepatitis B Virus Infection) (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2369  | Necrotizing Fasciitis (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2370  | Necrotizing Fasciitis (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2371  | Renal Impairment [Acute or Unspecified] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2372  | Renal Impairment [Acute or Unspecified] (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2373  | Coagulopathy [Unspecified Cause] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2374  | Coagulopathy [Unspecified Cause] (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2375  | Rash [Erythematous, Macular, or Desquamating of Unspecified Cause] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2376  | Rash [Erythematous, Macular, or Desquamating of Unspecified Cause] (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2377  | Soft Tissue Necrosis (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2378  | Soft Tissue Necrosis (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2379  | Group A Streptococcus (Tests for Group A Strep in Specimen from Nonsterile Site by Culture and Identification Method) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2380  | Organisms (Tests in Specimen from Nonsterile Site by Culture and Identification) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2381  | Specimen from a Nonsterile Site (Specimen Type) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2382  | Chagas Disease (Tests for Trypanosoma cruzi in specimen from donor) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2383  | Absence of Skin Lesions (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2384  | Neuralgia (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2385  | Neuralgia (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2386  | Peripheral Nerve Thickening (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2387  | Nerve (Specimen Type) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2388  | Hansen’s Disease (Tests for M. leprae or M. lepromatosis Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.239  | Chlamydia trachomatis Infection (Tests for Chlamydia trachomatis Nucleic Acid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.240  | Chlamydia trachomatis Infection (Tests for Chlamydia trachomatis Antigen) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2403  | NU_Hepatitis D Virus Infection (Tests for hepatitis D virus Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2404  | Hepatitis D Virus Infection (Tests for hepatitis D virus IgG Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2405  | Hepatitis D Virus Infection (Test for hepatitis D virus Antigen) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2406  | Hepatitis B Virus Infection (Combination Tests that include hepatitis B virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2407  | Firearm Injury (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2408  | Firearm Injury (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2409  | Babesiosis (Tests for B. microti IgG or Total Antibody [Titer]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2410  | Babesiosis (Tests for B. divergens IgG or Total Antibody [Titer]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2411  | Babesiosis (Tests for B. duncani IgG or Total Antibody [Titer]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2412  | Babesiosis (Tests for Babesia species IgG or Total Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2413  | Brucellosis (Tests for Brucella species IgG Antibody by ELISA) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2414  | Cranial Nerve Involvement (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2415  | Cranial Nerve Involvement (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2416  | Unusual Change in Behavior (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2417  | Radiculitis (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2418  | Subarachnoid Hemorrhage (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2419  | Subarachnoid Hemorrhage (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2420  | Discitis (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2421  | Discitis (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2423  | Respiratory Insufficiency [Unspecified Cause] (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2424  | Respiratory Insufficiency [Unspecified Cause] (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2425  | Conjunctival Suffusion (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2426  | Leptospira species (Tests by Microscopic Observation) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2427  | Leptospirosis (Tests for Leptospira Antibody by Agglutination) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2428  | Leptospirosis (Tests for Leptospira Antibody by Indirect Immunofluorescence) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2429  | Conjunctival Suffusion (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2430  | Pleural effusion (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2431  | Pleural effusion (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2432  | Abdominal swelling (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2433  | Abdominal swelling (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2434  | Neck swelling (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2435  | Neck swelling (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2436  | Diaphoresis (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2437  | Diaphoresis (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2438  | Edema (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2439  | Edema (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.244  | Gonorrhea (Tests for Neisseria gonorrhoeae Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2440  | Anthrax (Tests for Bacillus anthracis Protective Antigen Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2441  | Anthrax (Tests for Bacillus species by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2442  | Anthrax [Anthrax toxin lethal factor] (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2443  | Influenza A (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2444  | Influenza B (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2445  | Influenza [Unspecified] (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2446  | Influenza A (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2447  | Influenza [Unspecified] (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2448  | Influenza (Tests for unspecified influenza virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2449  | Influenza (Tests for influenza B virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2450  | Influenza (Tests for unspecified influenza virus Antigen) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2451  | Influenza (Tests for influenza B virus Antigen) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2452  | Influenza (unspecified influenza virus in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2453  | Influenza (influenza B virus in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2454  | Influenza (Tests for unspecified influenza virus by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2455  | Influenza (Tests for influenza B virus by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2456  | Hepatitis B Virus Infection (Tests for Hepatitis B Virus Total Core Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2457  | Hepatitis C Virus Infection (Combination Tests that include hepatitis C virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2458  | Louseborne relapsing fever (Tests for Borrelia recurrentis Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2459  | Louseborne relapsing fever (Tests for Borrelia recurrentis Nucleic Acid in Blood) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2460  | Borrelia species (Tests by Microscopic Observation) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2461  | Borrelia species (Tests by Microscopic Observation in Blood) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2462  | Spirochetes (Tests by Microscopic Observation) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2463  | Carbapenem Resistant Enterobacterales (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2464  | CP_ Carbapenem Resistant Enterobacterales (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2465  | CRE (Tests for Enterobacterales species [excluding Proteus spp., Providencia spp., and Morganella spp.] by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2466  | CRE (Tests for Proteus spp., Providencia spp., and Morganella spp. by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2467  | CRE (Tests for Enterobacterales species Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2468  | CRE (Combination Tests that include Enterobacterales by Culture and Identification) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2469  | Tests for Carbapenem Susceptibility [Meropenem and Doripenem] | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2470  | Enterobacterales species [excluding Proteus spp., Providencia spp., and Morganella spp.] (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2471  | Proteus spp., Providencia spp., and Morganella spp. (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2473  | Enterobacterales species [Carbapenem Resistant] (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2474  | Enterobacterales species [Carbapenemase Producing] (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2475  | Aortic valve stenosis (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2476  | Aortic valve stenosis (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2477  | Anotia (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2478  | Microtia (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2479  | Microtia (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2480  | Anotia (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2482  | Anophthalmia (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2483  | Anophthalmia (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2484  | Microphthalmia (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2485  | Microphthalmia (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2486  | Atrial septal defect (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2487  | Atrial septal defect (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2488  | Fetal Aortic valve stenosis (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2489  | Congenital Posterior Urethral Valves (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2490  | Congenital Posterior Urethral Valves (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2491  | Bladder Exstrophy (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2492  | Bladder Exstrophy (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2493  | Encephalocele (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2494  | Fetal Encephalocele (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2495  | Encephalocele (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2496  | Choanal Atresia (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2497  | Choanal Atresia (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2498  | Cloacal Exstrophy (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2499  | Cloacal Exstrophy (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2500  | Renal Agenesis or Hypoplasia (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2501  | Renal Agenesis or Hypoplasia (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2502  | Trisomy 13 (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2503  | Trisomy 13 (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2504  | Fetal Trisomy 13 (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2505  | Trisomy 13 (Tests for Trisomy 13 Chromosomal Anomaly) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2506  | Galactosemia (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2507  | Galactosemia (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2508  | Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative] in Blood) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2509  | Galactosemia (Tests for Galactokinase (GALK) [Quantitative] in Blood) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2510  | Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative] in Blood) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2511  | Galactosemia (Tests for Galactose_1_Phosphate Uridyltransferase [Quantitative]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2512  | Galactosemia (Tests for Galactokinase (GALK) [Quantitative]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2513  | Galactosemia (Tests for UDP_galactose 4' epimerase (GALE) [Quantitative]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2514  | Galactosemia (Tests for GALT gene allele 1) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2515  | Galactosemia (Tests for GALT gene allele 2) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2516  | Hypospadias (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2517  | Hypospadias (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2518  | Trisomy 18 (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2519  | Fetal Trisomy 18 (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2520  | Fetal Trisomy 18 (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2521  | Trisomy 18 (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2522  | Trisomy 18 (Tests for Trisomy 18 Chromosomal Anomaly) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2523  | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2524  | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2525  | Chlamydia trachomatis Infection (Tests for unspecified Chlamydia species Antigen) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2526  | Chlamydia trachomatis Infection (Combination Tests that include Chlamydia trachomatis Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2527  | Chlamydia species [Unspecified] (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2528  | Ventricular septal defect (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2529  | Ventricular septal defect (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2530  | Gonorrhea (Combination Tests that include Neisseria Gonorrhea Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2531  | Intracellular Gram Negative Diplococcus (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2532  | Congenital Cytomegalovirus (Tests for CMV Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.2533  | Congenital Cytomegalovirus (Tests for CMV Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.264  | Viral Hemorrhagic Fever (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.265  | Viral Hemorrhagic Fever (Disorders) (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.268  | Mumps (Tests for mumps virus IgM Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.272  | Present or Positive Lab Result Value | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.282  | Varicella (Tests for Varicella zoster virus by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.283  | Varicella (Tests for Varicella zoster virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.285  | Encephalitis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.287  | Varicella (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.289  | Carbon Monoxide Poisoning (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.293  | Toxic Effects of Lead (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.297  | Measles (Tests for measles virus Nucleic Acid) | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.299  | Measles (Tests for measles virus IgM Antibody) | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.300  | Meningococcal Disease (Organism or Substance in Lab Results) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.301  | Shigellosis (Tests for Shigella species by Culture and Identification Method) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.304  | Pesticide Related Illness (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.305  | Organisms (Tests by Microscopic Observation in Specimen from Normally Sterile Site by Gram Stain) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.307  | Leptospirosis (Tests for Leptospira IgM Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.308  | Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.310  | Bacteria (Tests by Culture and Identification Method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.311  | Viruses (Tests by Culture and Identification Method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.316  | Rubella (Tests for rubella virus IgM Antibody) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.317  | Shigellosis (Tests for Shigella species Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.319  | Fungi (Tests by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.322  | Pesticide Related Illness (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.326  | Arboviral Disease [Other] (Disorders) (ICD10CM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.329  | Apnea (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.330  | Apnea (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.333  | Shigellosis (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.335  | Influenza (Tests for influenza A virus by Culture and Identification Method) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.336  | Influenza (Tests for influenza A or B virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.340  | Influenza (influenza A or B virus in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.341  | Campylobacteriosis (Organism or Substance in Lab Results) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.342  | Campylobacteriosis (Tests for Campylobacter species by Culture and Identification Method) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.343  | Campylobacteriosis (Tests for Campylobacter species Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.344  | Campylobacteriosis (Tests for Campylobacter species Antigen) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.349  | Hepatitis A (Tests for hepatitis A virus IgM Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.353  | Diarrhea (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.356  | HIV Infection (Organism or Substance in Lab Results) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.359  | Botulism (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.362  | Hansen’s Disease (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.365  | Silicosis (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.366  | Silicosis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.371  | Cryptosporidiosis (Organism or Substance in Lab Results) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.372  | Cryptosporidiosis (Tests for Cryptosporidium species Nucleic Acid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.375  | Cyclosporiasis (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.376  | Cyclosporiasis (Tests for Cyclospora cayetanensis Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.379  | Giardiasis (Tests for Giardia species Nucleic Acid) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.384  | Listeriosis (Tests for Listeria monocytogenes Nucleic Acid) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.386  | Vibriosis (Organism or Substance in Lab Results) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.388  | Vibriosis (Tests for Vibrionaceae species [except Toxigenic Vibrio cholera O1 and O139] Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.390  | Trichinellosis (Tests for Trichinella species Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.395  | Syphilis (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.396  | Syphilis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.398  | Hepatitis C Virus Infection (Tests for hepatitis C virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.399  | Hepatitis C Virus Infection (Tests for hepatitis C virus Antigen) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.40  | STEC Infection (Disorders) (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.400  | Hepatitis B Virus Infection (Tests for hepatitis B virus IgM Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.401  | Hepatitis B Virus Infection (Tests for hepatitis B virus surface Antigen) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.403  | Hepatitis B Virus Infection (Tests for hepatitis B virus Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.405  | Hantavirus Infection and Diseases (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.407  | Hepatitis C Virus Infection (Tests for hepatitis C virus Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.408  | Hepatitis B Virus Infection (Organism or Substance in Lab Results) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.422  | Tuberculosis (Disorders) (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.427  | STEC Infection (Tests for Shiga toxin genes, or STEC, EHEC, or E. coli O157 Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.43  | Gonorrhea [Cervicitis Urethritis] (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.436  | Coccidioidomycosis (Tests for Coccidioides species IgM Antibody) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.437  | Coccidioidomycosis (Tests for Coccidioides species Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.438  | Coccidioidomycosis (Tests for Coccidioides species Antigen) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.44  | Gonorrhea [Cervicitis Urethritis] (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.445  | Legionellosis (Tests for Legionella species Antigen) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.446  | Legionellosis (Tests for Legionella species Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.451  | Tuberculosis (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.460  | HIV Infection or AIDS (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.464  | Malaria (Tests for Plasmodium species Nucleic Acid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.468  | Leptospirosis (Tests for Leptospira Nucleic Acid) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.471  | Leptospirosis (Tests for Leptospira Antibody [Quantitative] by Agglutination) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.472  | Leptospirosis (Tests for Leptospira Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.476  | Babesia species (Tests by Microscopic Observation in Blood) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.478  | Anthrax (Tests for Bacillus anthracis by Culture and Identification Method) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.479  | Anthrax (Tests for Bacillus anthracis Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.48  | Salmonellosis (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.480  | Anthrax (Tests for Bacillus anthracis Antigen) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.481  | Anthrax (Tests for Bacillus anthracis Antibody) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.494  | Ehrlichiosis (Organism or Substance in Lab Results) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.496  | Q Fever (Tests for Coxiella burnetii IgM IgG Antibody [Excluding Quantitative IFA Tests for IgG Antibody against Phase I or II Antigen]) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.500  | Q Fever (Tests for Coxiella burnetii Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.505  | Toxic Shock Syndrome (TSS) (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.507  | Toxic Shock Syndrome (TSS) (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.512  | Brucellosis (Tests for Brucella species Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.515  | Brucellosis (Tests for Brucella species Antibody [Quantitative]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.516  | Brucellosis (Organism or Substance in Lab Results) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.519  | Dengue Virus Infection (Tests for dengue virus Nucleic Acid) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.523  | Dengue Virus Infection (Tests for dengue virus Antigen) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.524  | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Quantitative]) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.525  | Dengue Virus Infection (Tests for dengue virus IgM Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.527  | Dengue Virus Infection (Tests for dengue virus IgG or Total Antibody [Qualitative]) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.530  | Borrelia species (Tests for Nucleic Acid) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.531  | Lyme Disease (Tests for Borrelia burgdorferi IgM IgG Antibody by Immunoblot) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.532  | Lyme Disease (Tests for Borrelia burgdorferi Antibody by Immunoassay) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.534  | Smallpox (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.542  | Spotted Fever Rickettsiosis (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.548  | St. Louis Encephalitis Virus Infection (Tests for Saint Louis encephalitis virus Antibody [Qualitative]) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.550  | Syphilis (Tests for Treponema pallidum Nucleic Acid) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.553  | Anaplasma species (Tests by Microscopic Observation) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.555  | Yellow Fever (Tests for yellow fever virus Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.557  | Yellow Fever (Tests for yellow fever virus Antibody [Quantitative]) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.56  | Diarrhea (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.560  | West Nile Virus Infection (Tests for West Nile virus Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.569  | Plague (Tests for Yersinia pestis Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.575  | Arboviral Disease [Other] (Tests for Arbovirus [Other] Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.576  | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antigen) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.577  | Arboviral Disease [Other] (Tests for Arbovirus [Other] IgM Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.578  | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Quantitative]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.579  | Arboviral Disease [Other] (Tests for Arbovirus [Other] Antibody [Qualitative]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.58  | Pertussis (Tests for Bordetella pertussis Nucleic Acid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.580  | Arboviral Disease [Other] (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.581  | Viral Hemorrhagic Fever (Tests for Viral Hemorrhagic Fever Virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.584  | Viral Hemorrhagic Fever (Tests for Viral Hemorrhagic Fever Virus IgG Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.586  | Viral Hemorrhagic Fever (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.595  | Tularemia (Tests for Francisella tularensis Nucleic Acid) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.598  | Tularemia (Tests for Francisella tularensis Antibody) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.6  | Diphtheria (Disorders) (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.605  | Organisms (Tests by Microscopic Observation by Acid Fast Stain) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.606  | Tuberculosis (Organism or Substance in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.614  | Pertussis (Tests for Bordetella pertussis Toxin Antibody) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.621  | Inspiratory Whoop (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.632  | Chlamydia trachomatis Infection [Secondary Sites Complications] (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.645  | Pertussis (Test Panels for Bordetella pertussis and Bordetella parapertussis Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.648  | Vomiting (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.650  | Jaundice (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.652  | Bacteria (Tests in Specimen from Normally Sterile Site by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.660  | Hypertonia [Excluding Congenital Hypertonia] (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.662  | Chest Pain (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.663  | Erythema Nodosum (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.664  | Congenital Zika Syndromes (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.665  | Congenital Zika Syndromes (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.666  | Guillain Barré syndrome (Disorders) (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.668  | Rash (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.671  | Fever (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.672  | Arthralgia (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.673  | Arthralgia (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.674  | Conjunctivitis (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.675  | Conjunctivitis (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.676  | Pregnant (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.677  | Postpartum (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.678  | Postpartum (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.679  | Hearing Loss (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.680  | Abdominal Pain (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.681  | Abdominal Pain (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.686  | Erythema Multiforme (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.687  | Myalgia (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.689  | Periorbital Edema (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.691  | Eosinophilia (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.692  | Eosinophilia (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.70  | Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi by Culture and Identification Method) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.702  | Weight Loss (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.705  | Syphilis (Tests for Treponemal or Non Treponemal Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.709  | Cough [Non Productive] (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.71  | Salmonellosis (Tests for Salmonella except S. typhi and S. paratyphi Nucleic Acid) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.711  | Wound Infection (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.712  | Pneumonia (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.713  | Sepsis [Septicemia] [Unspecified Organism] (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.714  | Sepsis [Septicemia] [Unspecified Organism] (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.715  | Meningitis (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.717  | Cellulitis (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.718  | Cellulitis (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.719  | Myositis [Unspecified Cause] (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.720  | Myositis [Unspecified Cause] (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.721  | Otitis Media (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.722  | Otitis Media (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.723  | Otitis Externa (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.724  | Otitis Externa (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.727  | Acute Upper Respiratory Illness (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.728  | HIV Infection (Tests for HIV Nucleic Acid [Qualitative]) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.730  | HIV Infection (Tests for HIV Antibody) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.733  | Perinatal Hepatitis B Virus Infection (Disorders) (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.741  | Hepatitis B Immune Globulin (RXNORM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.744  | Coccidioidomycosis (Tests for Coccidioides species IgG Antibody) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.746  | Treponema pallidum (Tests by Microscopic Observation) | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.747  | Penicillin G [Benzathine] [Injectable] [Bicillin] (RXNORM) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.750  | Chest Pain (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.755  | Acute Upper Respiratory Illness (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.756  | Purpura (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.757  | Muscle Spasms (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.758  | Muscle Spasms (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.762  | Mumps (Test Panels for mumps virus IgM IgG Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.763  | Parotitis [Unspecified Cause] (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.764  | Mumps (Tests for mumps virus IgG Antibody) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.765  | Aseptic Meningitis (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.766  | Encephalitis (Disorders) (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.767  | Hearing Loss (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.770  | Invasive Pneumococcal Disease (Tests for Streptococcus pneumoniae Nucleic Acid in Specimen from Normally Sterile Site) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.773  | Invasive Haemophilus influenzae Disease (Tests for Haemophilus influenzae Nucleic Acid in Specimen from Normally Sterile Site) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.777  | Mastitis (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.779  | Pancreatitis (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.780  | Pancreatitis (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.782  | Rubella (Test Panels for rubella virus IgM IgG Antibody) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.785  | Opioid Overdose and Poisoning (Tests for Opioids [Qualitative]) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.789  | Purpura (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.79  | Campylobacteriosis (Disorders) (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.792  | Novel Influenza A Virus Infection (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.793  | Novel Influenza A Virus Infection (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.794  | Sore Throat (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.795  | Influenza (influenza A virus in Lab Results) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.796  | Influenza (Novel influenza A virus in Lab Results) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.797  | Influenza (Tests for influenza A or B virus by Culture and Identification Method) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.798  | Influenza (Tests for influenza A virus Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.799  | Influenza (Tests for influenza A virus Antigen) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.802  | Influenza (Tests for Novel influenza A virus Nucleic Acid) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.803  | Tests by Microscopic Observation in Tissue by H&E or PAS Stain | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.808  | Headache (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.809  | Headache (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.810  | Backache (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.811  | Backache (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.815  | NU_Anaplasmosis (Tests for Anaplasma species Antibody [Qualitative]) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.816  | Rubella (Tests for rubella virus IgG Antibody [Ratio] in Serum) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.818  | Measles (Tests for measles virus IgG Antibody [Ratio] in Serum) | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.820  | Rubella (Tests for rubella virus IgG Antibody [Quantitative] in Serum) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.822  | Pneumoconiosis (Unspecified) (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.823  | Pneumoconiosis (Unspecified) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.824  | Computerized Tomography of Chest (Imaging) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.830  | Poliovirus Infection (Tests for Poliovirus Antibody Titer in Serum Specimen) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.835  | Lead in Blood (Disorders) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.836  | Lead in Blood (Disorders) (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.839  | Acid Fast Bacilli (Organism or Substance in Lab Results) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.841  | Tuberculosis (Interferon Gamma Release Assays) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.842  | Tests by Microscopic Observation in Tissue | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.844  | Tuberculosis (Second Line Drugs for Treatment) (RXNORM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.846  | SARS (Tests for SARS_CoV by Culture and Identification Method) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.847  | SARS (Tests for SARS_CoV Nucleic Acid) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.86  | Hemolytic Uremic Syndrome (HUS) (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.864  | Nausea (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.865  | Confusion (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.867  | Dyspnea (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.869  | Loss of Consciousness (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.87  | Thrombotic Thrombocytopenic Purpura (TTP) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.875  | SARS (Organism or Substance in Lab Results) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.878  | MERS (Tests for MERS_CoV Nucleic Acid) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.88  | Hemolytic Uremic Syndrome (HUS) (Disorders) (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.881  | Difficulty Breathing (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.884  | Tests by Microscopic Observation in Blood | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.889  | Hantavirus Infection (Tests for Hantavirus IgM IgG Total Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.892  | Organisms (Tests by Microscopic Observation in Tissue by Acid Fast Stain) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.895  | Rhinorrhea (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.896  | Tests by Microscopic Observation in Blood Smear | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.897  | Dengue Virus Infection (Test Panels for dengue virus IgM IgG Antibody) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.9  | Xray of Chest (Imaging) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.90  | Cough (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.900  | Organisms (Tests by Microscopic Observation) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.902  | Acute Renal Failure [Unspecified Cause] (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.907  | Arthritis [Unspecified Cause] (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.91  | Cough (SNOMED) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.910  | Epididymitis [Unspecified Cause] (SNOMED) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.911  | Epididymitis [Unspecified Cause] (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.914  | Osteomyelitis [Unspecified Cause] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.915  | Osteomyelitis [Unspecified Cause] (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.918  | Spondylitis [Unspecified Cause] (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.919  | Arthritis [Unspecified Cause] (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.92  | Thrombotic Thrombocytopenic Purpura (TTP) (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.927  | Thrombocytopenia [Unspecified Cause] (ICD10CM) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.928  | Bleeding [Unspecified Cause] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.930  | ECG Abnormalities [Unspecified Cause] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.931  | Hematemesis [Unspecified Cause] (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.932  | Hematemesis [Unspecified Cause] (ICD10CM) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.934  | Hematuria [Unspecified Cause] (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.935  | Hemoptysis (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.937  | Gastrointestinal Hemorrhage [Unspecified Cause] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.942  | Petechiae [Non Traumatic] (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.952  | Thrombocytopenia [Unspecified Cause] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.956  | Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.957  | Regional Lymphadenitis [Including Bubo] (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.958  | Regional Lymphadenitis (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.96  | Salmonellosis [Salmonella Species and Subspecies] (Organism or Substance in Lab Results) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.963  | Arboviral Disease [Other] (Disorders) (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.965  | Proteinuria [Unspecified Cause] (ICD10CM) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.969  | Proteinuria [Unspecified Cause] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.970  | Bulbar Weakness (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.971  | Bulbar Weakness (ICD10CM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.976  | Dysphagia (SNOMED) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.978  | Impaired Respiration [Unspecified Cause] (SNOMED) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.979  | Botulism (Organism or Substance in Lab Results) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.98  | Shigellosis (Disorders) (SNOMED) | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.989  | Tests for Mycobacterium species by Culture and Identification Method | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.991  | Rifampin (RXNORM) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.994  | Organisms (Tests for Nucleic Acid) | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.998  | Shigellosis (Tests for Enteroinvasive E. coli Nucleic Acid) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.999  | Chlamydia species (Organism or Substance in Lab Results) | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.109  | Pressure Injury Stage 2, 3, 4 or Unstageable | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.110  | Pressure Injury Stage 2, 3, 4 or Unstageable | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.112  | Pressure Injury Deep Tissue | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.113  | Pressure Injury Stage 2, 3, 4 or Unstageable | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.119  | Inpatient Falls | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.120  | Major Injuries | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.122  | Inpatient Falls | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.125  | Bleeding at Non Critical Site | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.130  | Anticoagulants for VTE Prophylaxis | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.131  | Anticoagulants for Indications Other than VTE Prophylaxis | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.135  | Bleeding at Critical Site | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.143  | Bleeding at Critical Site | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.144  | Bleeding at Critical Site | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.145  | Bleeding at Non Critical Site | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.146  | Bleeding at Non Critical Site | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.160  | Abdominal or Pelvic CT Scan with Contrast | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.163  | Ultrasound of Lower Extremities | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.164  | Ultrasound of Lower Extremities | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.165  | Ultrasound of Lower Extremities | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.171  | Inpatient Falls | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.183  | Anti Factor Xa Assay | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.187  | Extracorporeal Membrane Oxygenation (ECMO) | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.188  | Extracorporeal Membrane Oxygenation (ECMO) | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.190  | Intra Aortic Balloon Pump | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.191  | Intra Aortic Balloon Pump | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.193  | Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.194  | Pressure Injury Deep Tissue Diagnoses | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.196  | Pressure Injury Stage 2, 3, 4, or Unstageable Diagnoses | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.197  | Present on Admission or Clinically Undetermined | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1147.198  | Not Present On Admission or Documentation Insufficient to Determine | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.1  | DEXA Dual Energy Xray Absorptiometry, Bone Density | active | 2016-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.11  | Bladder Cancer Staging Ta for Urology Care | active | 2016-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.12  | Bladder Cancer staging T1 for Urology Care | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.13  | Bladder Cancer staging Tis for Urology Care | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.15  | Carcinoma of urinary bladder, superficial | active | 2016-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.16  | Injection Leuprolide Acetate | active | 2017-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.17  | High grade bladder cancer Ta for Urology Care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.18  | Immunocompromised state for Urology Care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.19  | Systemic chemotherapy for urology care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.2  | Bladder Cancer in Situ | active | 2016-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.20  | Corticosteroids for patients receiving Urology Care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.21  | Calcineurin inhibitors for patients receiving Urology Care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.23  | Immunomodulators for patients undergoing Urology Care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.24  | Monoclonal antibody for patient undergoing Urology Care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.28  | Radiotherapy for patients undergoing Urology Care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.29  | Plasmacytoid cell, morphologic abnormality for urology care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.3  | Bladder Cancer in Situ | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.30  | Sarcomatoid, morphologic abnormality for Urology Care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.31  | Micropapillary, morphologic abnormality, for Urology Care | active | 2017-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.32  | Immunosuppressive Drugs for Urology Care | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.38  | DEXA Dual Energy Xray Absorptiometry, Bone Density for Urology Care | active | 2017-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.39  | Mixed histology urothelial cell carcinoma for Urology Care | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.4  | BCG Bacillus Calmette Guerin, Tice | active | 2016-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.40  | Cystectomy for Urology Care | active | 2017-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.44  | Unavailability of Bacillus Calmette Guerin for urology care | active | 2017-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.45  | Bladder Cancer for Urology Care | active | 2017-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.48  | Androgen deprivation therapy for Urology Care | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.5  | BCG Bacillus Calmette Guerin, Connaught | active | 2016-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.52  | BCG Bacillus Calmette Guerin for Urology Care | active | 2020-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.53  | Cystectomy for Urology Care | active | 2018-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.54  | Acute Tuberculosis for Urology Care | active | 2018-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.55  | Cystectomy for Urology Care | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.56  | Active Tuberculosis for Urology Care | active | 2018-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.57  | Bladder Cancer Staging Tis for Urology Care | active | 2019-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.58  | Bladder Cancer Staging Tis for Urology Care | active | 2019-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.59  | Hospital Services for Urology | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.6  | Peripheral DXA Scan | active | 2016-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.60  | Chemotherapy Agents for Advanced Cancer | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.8  | Tuberculosis Diagnosis Prior to Urology Care | active | 2016-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1151.9  | Leukemia Diagnosis Prior to Urology Care | active | 2016-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.13  | Preventative Clinical Encounters | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.14  | Intensive Lifestyle Interventions | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.15  | Intensive Lifestyle Interventions | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.16  | Intensive Lifestyle Interventions | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.17  | Intensive lifestyle interventions | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.21  | Outpatient Clinical Encounters | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.22  | Outpatient Clinical Encounters | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.23  | Outpatient Clinical Encounters | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.24  | Outpatient Clinical Encounters | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.25  | Reason for No Intensive Lifestyle Intervention | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.27  | Type 2 Diabetes Diagnoses | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.28  | Type 2 Diabetes Diagnoses | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.29  | Type 2 Diabetes Diagnoses | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.30  | Prediabetes HbA1c Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.31  | Prediabetes HbA1c Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.32  | Prediabetes HbA1c Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.33  | Prediabetes Oral Glucose Tolerance Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.34  | Prediabetes Oral Glucose Tolerance Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.35  | Prediabetes Oral Glucose Tolerance Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.36  | Prediabetes Fasting plasma glucose or Plasma Glucose Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.37  | Prediabetes Fasting plasma glucose or Plasma Glucose Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.38  | Prediabetes Fasting plasma glucose or Plasma Glucose Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.4  | Glycemic Screening Tests | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.40  | Sickle Cell Disease with Vaso Occlusive Episode | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.41  | Sickle Cell Disease with Vaso Occlusive Episode | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.42  | Sickle Cell Disease with Vaso Occlusive Episode | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.43  | Analgesics for Acute Pain | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.49  | Medication Therapy Management Services for Essential Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.5  | Glycemic Screening Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.52  | Remote Physiologic Blood Pressure Monitoring | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.57  | Aldosterone Receptor Blocker for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.58  | Alpha Blocker for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.59  | Angiotensin Converting Enzyme Inhibitor for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.6  | Glycemic Screening Tests | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.60  | Angiotensin II Receptor Blocker for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.61  | Beta Blocker for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.62  | Calcium Channel Blocker Dihydropyridine for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.63  | Calcium Channel Blocker Non Dihydropyridine for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.64  | Central Acting for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.65  | Direct Renin Inhibitor for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.66  | Loop Diuretic for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.67  | Neuronal Blocking Agent for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.68  | Potassium Sparing Diuretic for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.69  | Thiazide Diuretic for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.7  | Preventative Clinical Encounters | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.70  | Vasodilator for Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.73  | Analgesics for Acute Pain (Non Parenteral Route) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.74  | Analgesics for Acute Pain (Parenteral Route) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.75  | Analgesics for Acute Pain Non Oral Enteral/Mucosal Routes | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.77  | Antihypertensive Medication Classes | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.78  | Medication Therapy Management Services for Essential Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.79  | Medication Therapy Management Services for Essential Hypertension | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.8  | Preventative Clinical Encounters | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.84  | Renal Colic | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.85  | Renal Colic | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.86  | Renal Colic | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.88  | Direct LDL Cholesterol | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.89  | Calculated LDL Cholesterol | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1160.9  | Preventative Clinical Encounters | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.50  | Urinary retention | active | 2017-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.51  | Urinary retention | active | 2017-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.52  | Urinary retention | active | 2017-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.65  | Morbid Obesity | active | 2018-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.66  | Morbid Obesity | active | 2018-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.67  | Morbid Obesity | active | 2018-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.68  | BMI greater than 40 | active | 2019-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1164.69  | Morbid Obesity | active | 2019-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.1  | Pregnancy Status | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.10  | Pap Smear Tests | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.103  | Female Sterilization HCPCS Devices | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.105  | Female Sterilization ICD10CM Provision Encounters | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.109  | Sterilization SNOMED Findings | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.11  | HIV Tests | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.110  | Pregnancy Bundle Visits | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.111  | Prenatal Care Specific Visits CPT | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.112  | Prenatal Care Specific Visits HCPCS | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.113  | Prenatal Care Specific Visits SNOMED | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.114  | Prenatal Care Specific Visits | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.115  | Self Identified Need for Contraception (SINC) | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.117  | Syphilis Tests | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.118  | Infecund Not for Contraceptive Reasons CPT Procedures | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.119  | Infecund Not for Contraceptive Reasons HCPCS Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.12  | Human Papilloma Virus Tests | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.120  | Prenatal Care Visits CPT | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.121  | Prenatal Care Visits HCPCS | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.122  | Prenatal Care Visits SNOMED | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.123  | Pregnancy Related Diagnoses ICD10CM | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.124  | Pregnancy Related Diagnoses SNOMED | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.125  | Non Live Birth Diagnoses ICD10CM | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.126  | Non Live Birth Diagnoses SNOMED | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.127  | Non Live Birth CPT Procedures | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.128  | Non Live Birth ICD10PCS Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.129  | Contraceptive Ring RXNORM Medications | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.13  | Chlamydia Trachomatis Tests | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.130  | Contraceptive Implants RXNORM Medications | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.131  | Injectable Contraceptive RXNORM Medications | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.132  | Oral Contraceptive Pills RXNORM Medications | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.133  | Pregnancy Related Diagnoses | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.134  | Female Sterilization SNOMED Provision Procedures | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.135  | General Prenatal Care Visits | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.136  | Non Live Birth Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.137  | Non Live Birth Diagnoses | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.138  | IUD Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.139  | IUD Provision Procedures | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.14  | Neisseria Gonorrhoeae Tests | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.140  | IUD Devices | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.141  | Contraceptive Patch SNOMED Devices | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.142  | Female Sterilization Provision Procedures | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.143  | Live Birth Delivery CPT Procedures | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.144  | Contraceptive Patch SNOMED Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.145  | Contraceptive Patch SNOMED Findings | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.146  | Contraceptive Patch ICD10CM Provision Encounters | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.147  | Contraceptive Patch ICD10CM Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.148  | Live Birth Delivery ICD10PCS Procedures | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.149  | Contraceptive Patch HCPCS Devices | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.15  | Chlamydia trachomatis and Neisseria Gonorrhoeae combined Tests | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.150  | Contraceptive Patch LOINC | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.151  | Infecund Not for Contraceptive Reasons Procedures | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.152  | Live Birth Delivery Procedures SNOMED CT | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.153  | Contraceptive Ring SNOMED Surveillance Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.154  | Contraceptive Ring SNOMED Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.155  | Contraceptive Ring SNOMED Findings | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.156  | Contraceptive Ring ICD10CM Provision Encounters | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.157  | Contraceptive Ring ICD10CM Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.159  | Contraceptive Ring HCPCS Devices | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.160  | Contraceptive Ring LOINC | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.161  | Contraceptive Implant SNOMED Devices | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.162  | Contraceptive Implant ICD10PCS Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.163  | Contraceptive Implant SNOMED Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.164  | Contraceptive Implant SNOMED Findings | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.165  | Infecund Not for Contraceptive Reasons SNOMED Procedures | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.167  | Contraceptive Implant LOINC | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.168  | Pregnancy Bundle CPT | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.169  | Pregnancy Bundle HCPCS | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.17  | Contraceptive Type | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.170  | Contraceptive Implant ICD10CM Provision Encounters | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.171  | Contraceptive Implant ICD10CM Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.173  | Contraceptive Implant HCPCS Devices | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.174  | Contraceptive Patch Devices | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.177  | Live Birth Delivery Procedures | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.178  | Contraceptive Ring Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.18  | Contraception Not Used Reason | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.180  | Contraceptive Implant CPT Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.181  | Injectable Contraceptive SNOMED Surveillance Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.182  | Injectable Contraceptive SNOMED Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.183  | Injectable Contraceptive SNOMED Findings | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.185  | Injectable Contraceptive ICD10CM Provision Encounters | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.186  | Injectable Contraceptive ICD10CM Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.187  | Injectable Contraceptive HCPCS Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.188  | Injectable Contraceptive LOINC | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.189  | Oral Contraceptive Pill SNOMED Surveillance Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.190  | Oral Contraceptive Pill SNOMED Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.191  | Oral Contraceptive Pill SNOMED Findings | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.192  | Contraceptive Implant SNOMED Surveillance Procedures | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.193  | Oral Contraceptive Pill ICD10CM Provision Encounters | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.194  | Oral Contraceptive Pill ICD10CM Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.195  | Oral Contraceptive Pill HCPCS Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.196  | Oral Contraceptive Pill LOINC | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.197  | Injectable Contraceptive Provision Procedures | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.198  | Injectable Contraceptive Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.199  | Oral Contraceptive Pill Provision Procedures | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.200  | Oral Contraceptive Pill Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.201  | Contraceptive Implant Devices | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.202  | Contraceptive Implant Provision Procedures | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.203  | Contraceptive Implant Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.204  | Prenatal Care Bundle CPT | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.205  | Prenatal Care Bundle Visits | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.206  | Infecund Not for Contraceptive Reasons ICD10PCS Procedures | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.209  | Yes and No Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.21  | Contraceptive Provision Method | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.210  | Pap Smear Results | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.211  | Contraceptive discussion | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.22  | Pregnancy Intention | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.24  | Clinical Provider Role | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.29  | Insurance Coverage Type | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.3  | Organism Detection | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.31  | English Proficiency | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.76  | Contraceptive Patch RXNORM Medications | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.78  | Intrauterine Devices CPT Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.79  | Intrauterine Devices HCPCS Devices | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.80  | Intrauterine Devices LOINC | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.81  | Intrauterine Devices HCPCS Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.83  | Intrauterine Devices ICD10CM Provision Encounters | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.84  | Intrauterine Devices ICD10CM Surveillance | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.85  | Intrauterine Devices RXNORM Medications | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.86  | Intrauterine Devices SNOMED Devices | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.87  | Intrauterine Devices SNOMED Findings | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.88  | Intrauterine Device SNOMED Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.89  | Intrauterine Devices SNOMED Surveillance Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.91  | Intrauterine Devices ICD10PCS Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.93  | Female Sterilization CPT Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.96  | Infecund Not for Contraceptive Reasons SNOMED Findings | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.97  | Infecund Not for Contraceptive Reasons ICD10CM | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.98  | Female Sterilization LOINC | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1166.99  | Female Sterilization ICD10PCS Provision Procedures | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.10  | ASN Screening Declined | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.11  | Transportation Insecurity Diagnosis | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.12  | Food Insecurity Diagnosis | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.13  | Homelessness Diagnosis | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.14  | Housing Instability Diagnosis | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.15  | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.16  | Intervention for Positive Food Insecurity Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.17  | Intervention for Positive Food Insecurity Screen | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.18  | Intervention for Positive Food Insecurity Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.19  | Intervention for Positive Food Insecurity Screen | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.2  | Intracranial or Intraspinal surgery | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.20  | Intervention for Positive Homelessness Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.21  | Intervention for Positive Housing Instability Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.22  | Emergency Department Observation | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.27  | Mental Health Diagnosis without Substance Use Disorders | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.28  | Mental Health Diagnosis without Substance Use Disorders | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.29  | Bed Assigned | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.3  | Malignant Intracranial Neoplasm Group | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.31  | Healthcare Agent & Power of Attorney Documentation | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.32  | Healthcare Agent and Power of Attorney Documentation | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.33  | Advance Directive Documentation | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.34  | Advance Directive Documentation | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.35  | Advance Directive Documentation | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.36  | Portable Medical Order(s) Documentation | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.37  | Portable Medical Order(s) Documentation | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.38  | Advance Care Planning Discussion Documentation | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.4  | Thrombolytic medications | active | 2021-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.40  | Advance Care Planning Documentation | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.41  | Advance Care Planning Documentation | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.42  | Healthcare Agent & Power of Attorney Documentation | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.43  | Advance Directive Documentation | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.45  | Advance Care Planning Documentation | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.46  | Advance Care Planning Documentation | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.47  | Portable Medical Order(s) Documentation | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.48  | Portable Medical Order(s) Documentation | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.49  | Intervention for Positive Utility Insecurity Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.5  | Allergy to thrombolytics | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.50  | Intervention for Positive Utility Insecurity Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.51  | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.52  | Intervention for Positive Transportation Insecurity Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.53  | Intervention for Positive Housing Instability Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.54  | Intervention for Positive Housing Instability Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.55  | Intervention for Positive Homelessness Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.56  | Intervention for Positive Homelessness Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.57  | Non Invasive Oxygen Therapy Device Codes | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.58  | Goals, preferences, and priorities for medical treatment | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.6  | Thrombolytics Adverse Event | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.7  | Intraspinal surgery | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.8  | Intervention for Positive Utility Insecurity Screen | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1170.9  | Utility Insecurity Diagnosis | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1176.58  | Food Insecurity Screening Positive | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.1  | Ezetimibe Therapy | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.10  | Antihypertensive Medications | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.100  | Allergy or Intolerance to ACE Medication | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.101  | Allergy or Intolerance to ARB Medication | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.102  | Chronic Kidney Disease Stage 1 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.103  | Chronic Kidney Disease Stage 2 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.104  | Chronic Kidney Disease Stage 3 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.105  | Chronic Kidney Disease Stage 4 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.106  | Chronic Kidney Disease Stage 5 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.107  | ICD10 CM Chronic Kidney Disease Stage 1 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.108  | ICD10 CM Chronic Kidney Disease Stage 2 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.111  | AHA GWTG Chronic Kidney Disease Stage 2 | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.112  | ICD10 CM Chronic Kidney Disease Stage 3 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.113  | ICD10 CM Chronic Kidney Disease Stage 4 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.114  | ICD10 CM Chronic Kidney Disease Stage 5 | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.115  | AHA GWTG Chronic Kidney Disease Stage 1 | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.116  | AHA GWTG Chronic Kidney Disease Stage 3 | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.117  | AHA GWTG Chronic Kidney Disease Stage 4 | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.118  | SNOMED CT Atrial Fibrillation | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.119  | ICD10 CM Atrial Fibrillation | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.121  | AHA GWTG Atrial Fibrillation | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.123  | SNOMED CT Hyperlipidemia | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.124  | ICD10 CM Hyperlipidemia | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.125  | AHA GWTG Hyperlipidemia | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.126  | SNOMED CT Hypertriglyceridemia | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.127  | ICD10 CM Hypertriglyceridemia | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.129  | AHA GWTG Hypertriglyceridemia | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.130  | SNOMED CT Gestational Diabetes | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.131  | ICD10 CM Gestational Diabetes | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.132  | AHA GWTG Gestational Diabetes | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.133  | SNOMED CT Hyperglycemia | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.134  | ICD10 CM Hyperglycemia | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.135  | AHA GWTG Hyperglycemia | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.136  | SNOMED CT Nonobstructive CAD | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.137  | ICD10 CM Nonobstructive Coronary Artery Disease | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.138  | AHA GWTG Nonobstructive coronary artery disease | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.139  | AHA GWTG Anti Obesity Pharmacotherapy | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.15  | Non Tobacco Smoking Product User | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.16  | Antihypertensive Fixed Dose Combination Medications | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.2  | PCSK9 Inhibitors | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.20  | CCB and Thiazide and Thiazide Like Diuretics | active | 2021-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.21  | Referral to cardiac rehab | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.22  | Cardiac Rehabilitation | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.25  | 2 Hour Blood Glucose Test | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.26  | NYHA Functional Classification | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.27  | ARNI Therapy | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.29  | MRA Therapy | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.3  | Cholesterol non HDL Laboratory Test | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.30  | SGLT2 Inhibitors | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.31  | Heart Transplant | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.32  | Heart Transplant | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.33  | Heart Transplant | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.34  | Allergy to MRA Therapy | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.35  | Aspirin or Clopidogrel | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.39  | Cardiac Rehabilitation | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.4  | Hypothyroidism | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.40  | Cardiac Rehabilitation | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.43  | SGLT2 Ingredients | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.44  | MRA Ingredients | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.49  | Minnesota Living with Heart Failure Questionnaire | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.5  | Hypothyroidism | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.50  | Kansas City Cardiomyopathy Questionnaire | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.51  | Cardiac Pacer | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.52  | Cardiac Pacer | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.53  | Cardiac Pacer | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.54  | Heart Transplant Complications | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.55  | Heart Transplant Complications | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.56  | Heart Transplant Complications | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.57  | Left Ventricular Assist Device Complications | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.58  | Left Ventricular Assist Device Complications | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.59  | Left Ventricular Assist Device Placement | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.6  | Hypothyroidism | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.60  | Left Ventricular Assist Device Placement | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.61  | Left Ventricular Assist Device Placement | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.62  | Left Ventricular Assist Device Placement | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.63  | Heart Transplant | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.65  | Cardiac Pacer | active | 2022-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.66  | Diastolic Heart Failure | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.67  | Diastolic Heart Failure | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.68  | Diastolic Heart Failure | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.69  | Allergy to SGLT2 Inhibitors | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.7  | Anorexia Nervosa | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.70  | Intolerance to SGLT2 Inhibitors | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.71  | Intolerance to MRA Therapy | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.72  | ARNI Ingredient | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.73  | Mitral Stenosis | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.74  | Mitral Stenosis | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.75  | Mitral Stenosis | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.76  | Mechanical Prosthetic Heart Valve | active | 2022-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.77  | Mechanical Prosthetic Heart Valve | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.78  | Mechanical Prosthetic Heart Valve | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.79  | Mechanical Prosthetic Heart Valve in Situ | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.8  | Anorexia Nervosa | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.82  | Systolic Heart Failure | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.83  | Systolic Heart Failure | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.84  | Systolic Heart Failure | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.85  | Carotid Intervention | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.86  | Serum Creatinine | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.87  | Urine Creatinine | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.88  | Urine Albumin | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.9  | Anorexia Nervosa | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.90  | Non Steroidal Mineralcorticoid Receptor Antagonist | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.91  | Glucagon like peptide 1 medications | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.96  | AHA GWTG Long COVID19 | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.97  | AHA GWTG Long COVID19 SNOMEDCT | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1178.98  | AHA GWTG Long COVID19 ICD10CM | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.1  | Wound internal item and/or body structure visible value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.11  | Wound exudate appearance value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.12  | Wound exudate color value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.13  | Exudate odor value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.14  | Wound anatomic location value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.16  | Skin temperature value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.17  | Skin color enumerated value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.18  | Skin turgor value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.19  | Skin and mucous membrane integrity value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.2  | Periwound condition value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.20  | Skin moisture value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.3  | Wound Type Etiology value set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.4  | Wound episode value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.6  | Wound bed appearance value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.60  | Wound type reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.7  | Wound bed color value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.74  | Nonverbal pain indicators reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.76  | Pain associated signs and symptoms reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.77  | Pain body location reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.8  | Wound edge description value set (foundation metadata concept) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.80  | Pain quality reference set | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.81  | Pain speed of onset reference set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1181.9  | Presence absence value set (foundation metadata concept) | active | 2018-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.1  | Common drug substances for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.2  | Common drug classes for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.3  | Common dietary substances for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.4  | Common environmental substances for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.5  | Common refutations for substance causes for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.7  | Common substances for allergy and intolerance documentation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1186.8  | Common substances for allergy and intolerance documentation including refutations | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.10  | NHSNCriterionOfDiagnosisCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.11  | NHSNCriterionOfDiagnosisCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.12  | NHSNInfectionConditionCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.13  | NHSNInfectionConditionCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.14  | NHSNInfectionTypeCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.15  | NHSNInfectionTypeCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.16  | NHSNInfectionFirstReportedSource(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.17  | NHSNInfectionFirstReportedSource(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.18  | NHSNLOS/MENDischargeDisposition(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.19  | NHSNLOS/MENDischargeDisposition(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.20  | NHSNPopulationSummaryReportTypeCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.21  | NHSNPopulationSummaryReportTypeCode(LOINC) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.22  | NHSNSameDayOutcomeMeasure(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.23  | NHSNSameDayOutcomeMeasure(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.24  | NHSNSignificantPathogenCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.25  | NHSNSignificantPathogenCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.26  | NHSNSpinalFusionApproachCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.27  | NHSNSpinalFusionApproachCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.28  | NHSNVascularAccessTypeCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.29  | NHSNVascularAccessTypeCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.30  | NHSNVascularSpecimenCollectionSite(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.31  | NHSNVascularSpecimenCollectionSite(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.38  | Blood Glucose Laboratory and Point of Care Tests | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.58  | Diabetes Medications | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.6  | NHSNPathogenCodeARO | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.62  | Lab Tests for Clostridioides difficile | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.63  | Bacterial and Fungal Blood Culture Tests | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.7  | NHSNRoleOfPerformerCode(CDCNHSN) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.74  | Enteral Medication Route | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.75  | Intravenous Medication Route | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.76  | Fidaxomicin | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.77  | Vancomycin | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.78  | Metronidazole | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.79  | Fidaxomicin, Vancomycin, and Metronidazole | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.8  | NHSNRoleOfPerformerCode(SNOMEDCT) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.85  | Baloxavir | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.86  | Peramivir | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.87  | Zanamivir | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.88  | Digestive, Intramuscular, Intravenous Route of Administration | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.89  | Maternal Diagnoses | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.9  | NHSNRoleOfPerformerCode(HealthCareProviderTaxonomy) | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.90  | NHSN LTC AU Antimicrobial Agents | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.91  | Long Term Care Discharge Disposition | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.94  | NHSNNeurogenicBladder | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1190.95  | NHSNSpinalCordInjury | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1139  | S4G Hyperlipidemia | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1291  | S4G Cardiomyopathy | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1292  | S4G Tricuspid valve disorder | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1293  | S4G Pompe disease | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1294  | S4G Malignant hyperthermia | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1295  | S4G Malignancy | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1297  | S4G Intestinal polyp | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1298  | S4G Hamartoma | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1299  | S4G Diabetes mellitus | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1300  | S4G Muscular dystrophy and weakness | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1325  | S4G Hamartoma and S4G Intestinal Polyp | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1326  | S4G Malignancy and S4G Intestinal Polyp | active | 2022-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1344  | Tests for Neisseria gonorrhoeae of unspecified site reported by presence | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1352  | Body weight | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1354  | Cefixime preparations for oral administration | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1358  | Beta lactam medicinal product SNOMED | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.1370  | Beta lactam ingredients for allergy determination RXNORM | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.147  | SCIP Major Surgical Procedure | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.158  | Multiple Myeloma Regimen Drugs | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.226  | Opioids, All | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3483  | Financial Insecurity Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3484  | Food Insecurity Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3485  | Health Literacy Screening Assessments Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3486  | Homelessness Screening Assessments Questions | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3487  | Housing Instability Screening Assessments Questions | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3488  | Less Than High School Education Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3519  | Health Insurance Coverage Status Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.3520  | Inadequate Housing Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.393  | Hypoglycemics Severe Hypoglycemia | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.394  | Hypoglycemics Treatment Medications | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4436  | Gentamicin medications | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4437  | Azithromycin medications | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4448  | Lidocaine | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4466  | Pharyngeal specimens | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4467  | Urogenital & Anorectal Specimens | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4469  | Cabotegravir Injectable Products | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4470  | Emtricitabine oral for HIV PrEP | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4474  | HIV Laboratory Based Tests | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4502  | Ceftriaxone all code types | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.491  | Medium Dose ICS Formoterol Preparations | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.495  | ICS LABA LAMA Preparations | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.788  | Social Determinants of Health Conditions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.789  | Social Determinants of Health Procedures | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.790  | Social Determinants of Health Service Requests | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.93  | CPIC RxNORM abacavir SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.94  | CPIC RxNORM allopurinol SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.95  | CPIC RxNORM amitriptyline SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.96  | CPIC RxNORM atazanavir SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.97  | CPIC RxNORM atomoxetine SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.99  | CPIC RxNORM capecitabine SCDG | active | 2019-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.1  | Mechanical Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.10  | Surgical Site Bleeding and Other Surgical Site Complications | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.11  | Procedures Resulted From Surgical Site Bleeding and Other Surgical Site Complications | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.12  | Opioid (Oral Tablets and Patches only) | active | 2019-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.13  | Comorbidity Risk Factors | active | 2020-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.14  | Treatment of Hemorrhage or Hematoma | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.15  | General Surgery | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.17  | Coagulation Disorder Conditions | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.18  | Acute Respiratory Failure | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.19  | Anticoagulant Medications | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.2  | Fracture Exclusions For Hip And Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.20  | Anticoagulant Medications, Oral | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.21  | Anticoagulant Medications, Injection | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.28  | Active Bleeding | active | 2020-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.29  | Fall Risk Increasing Drugs (FRIDs) | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.3  | Pulmonary Embolism Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.30  | Fall Risk Factors | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.32  | Total Hip Arthroplasty Surgery | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.33  | Total Knee Arthroplasty Surgery | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.34  | AbnormalityOfGaitAndMobility | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.35  | Assymetry Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.36  | Hemiplegia Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.37  | Leg Weakness Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.38  | Osteopenia Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.39  | Stroke Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.4  | Sepsis Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.40  | Vestibular Symptoms | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.41  | TricyclicAntidepressants | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.42  | Benzodiazepines | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.43  | LoopDiuretics | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.44  | Antiepileptics | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.45  | Antipsychotics | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.46  | Opioid Medications | active | 2021-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.47  | Imaging Related to VTE | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.48  | Anticoagulant Medication | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.49  | VTE Diagnoses | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.5  | Nonprimary Total Hip, Total Knee Replacement | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.50  | Bisphosphonate Therapy | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.51  | VTE Symptoms | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.52  | Oncology Critical Care Units | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.53  | Provider Types | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.56  | FOBT_Lab | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.57  | Colorectal Screening | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.58  | Screening Mammogram (CPT) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.59  | Screening Mammogram (LOINC) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.6  | Pneumonia Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.60  | Screening Mammogram (SNOMEDCT) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.61  | Screening Mammogram (Grouping) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.62  | Diagnostic Mammography (CPT) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.63  | Diagnostic Mammography (LOINC) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.64  | Diagnostic Mammography (SNOMEDCT) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.65  | Diagnostic Mammography | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.66  | Breast Cancer Biopsy and Surgical Excision | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.67  | BI_RADS Categories 0, 4, and 5 | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.68  | BI_RADS Categories 1, 2, and 3 | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.7  | Malignant Neoplasm Complications Related To Hip and Knee Procedures | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.8  | Periprosthetic Joint Infection/Wound Infection and Other Wound Complications | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1206.9  | Procedures Resulted From Periprosthetic Joint Infection/Wound Infections | active | 2019-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.101  | Local Anesthetics | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.102  | Ophthalmic Epinephrines | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.103  | Inhaled Epinephrines | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.104  | Clopidogrels | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.105  | Cytochrome P450 2C19 inhibitors | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.106  | Cytochrome P450 2C9 inhibitors | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.107  | Aspirin Ingredient and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.109  | Oral Anticoagulant Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.110  | Corticosteroid Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.111  | Antidepressant Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.112  | PPI and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.113  | Antiplatelet Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.114  | NSAIDs Ingredients and Risk of GI Bleeding | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.115  | Kratom containing compounds | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.117  | Clopidogrel Ingredients and Risk of GI Bleeding | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.121  | Gastrointestinal bleeding episode and Risk of GI Bleeding 1 | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.122  | Gastrointestinal bleeding episode and Risk of GI Bleeding 2 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.123  | Gastrointestinal bleeding episode and Risk of GI Bleeding | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1213.24  | Oxycodones | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1217.2  | TESTSemanticBitsValueSet | active | 2020-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.1  | Bronchiectasis Disorder SNOMED | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.10  | Interstitial Lung Disease ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.100  | Occupational Therapy Procedure HCPCS | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.101  | Occupational Therapy Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.102  | Speech Language Therapy Procedure HCPCS | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.103  | Speech Language Therapy Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.104  | Home Health Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.105  | Intermittent Skilled Nursing Home Health Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.106  | pH, Hematocrit, Partial Pressure Carbon Dioxide, Partial Pressure Oxygen or Bicarbonate Laboratory Test for Breathing Assistance Device Evaluation Excluding Oxygen Saturation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.107  | Breathing Test Procedure During Sleep | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.108  | Ambulance Transport Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.109  | Prefabricated Spinal Orthotic Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.11  | Interstitial Lung Disease SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.110  | Custom Fitted Spinal Orthotic Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.111  | Custom Fabricated Spinal Orthotic Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.112  | Orthotic Device Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.113  | Spinal Orthotic Device or Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.115  | Spine or Neck Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.116  | Spine or Neck Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.117  | Spine or Neck Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.118  | Total Electric Hospital Bed Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.119  | Hypoventilation Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.12  | Interstitial Lung Disease | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.120  | Hypoventilation Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.121  | Hypoventilation Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.122  | Respiratory Assist Device Qualifying Condition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.123  | Apnea Hypopnea Index Rate Measurement | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.124  | Forced Expiratory Volume in One Second (FEV1)/Forced Vital Capacity (FVC) Measurement | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.125  | Maximal Inspiratory Pressure Measurement | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.126  | Forced Vital Capacity (FVC) Measurement by Spirometry | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.127  | Oxygen Saturation Measurement At Rest | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.128  | Respiratory Assist Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.129  | Respiratory Assist Device Supply | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.13  | Cystic Fibrosis Lung Disease ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.130  | Home Oxygen Therapy Accessory | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.131  | Forced Vital Capacity (FVC) Measurement Prediction | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.132  | Oxygen Saturation Laboratory Test and Setting for Breathing Assistance Device Evaluation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.133  | Respiratory Disturbance Index | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.134  | Sleep Related Symptom for Positive Airway Pressure Device Use Evaluation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.135  | Past Medical History Condition Related to Need for Positive Airway Pressure Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.136  | Home or Facility Care Location | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.137  | Fracture of Bone Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.138  | Fracture of Bone Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.139  | Fracture of Bone Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.14  | Cystic Fibrosis Lung Disease SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.140  | Severe Obesity Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.141  | Severe Obesity Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.142  | Severe Obesity Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.143  | Transfer from Bed Impairment SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.144  | Bed Confinement Impairment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.145  | Transfer from Bed Impairment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.146  | Ability to Safely Sit in Chair or Wheelchair Impairment SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.147  | Mobility Impairment or Fall From Chair ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.148  | Ability to Safely Sit in Chair or Wheelchair Impairment | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.149  | Fall or Fall Risk from Wheelchair or Stretcher SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.15  | Cystic Fibrosis Lung Disease | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.150  | Fall or Fall Risk from Wheelchair or Scooter ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.152  | Muscle, Tendon or Joint Contracture Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.153  | Muscle, Tendon or Joint Contracture Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.154  | Muscle, Tendon or Joint Contracture Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.155  | Muscle Weakness or Myasthenia Gravis Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.156  | Muscle Weakness or Myasthenia Gravis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.158  | Myocardial Infarction Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.159  | Myocardial Infarction Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.16  | Neoplasm of Lung or Trachea Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.160  | Myocardial Infarction Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.161  | Amputation Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.162  | Amputation Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.164  | Lower Extremity Deep Vein Thrombosis Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.165  | Lower Extremity Deep Vein Thrombosis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.167  | Spinal Cord Injury or Paralysis Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.168  | Spinal Cord Injury or Paralysis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.169  | Spinal Cord Injury or Paralysis Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.17  | Neoplasm of Lung or Trachea Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.170  | Demyelinating Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.171  | Demyelinating Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.172  | Demyelinating Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.173  | Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.174  | Grade 2, 3 or 4 Decubitus Ulcer on Buttock Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.176  | Wound Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.177  | Wound Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.178  | Wound Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.179  | Danger to Self or Others Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.18  | Neoplasm of Lung or Trachea Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.180  | Danger to Self or Others Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.181  | Danger to Self or Others Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.182  | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.183  | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.184  | Behavioral Disorder Related to Need for Non Emergency Ambulance Transfer | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.185  | Pain on Movement or Joint Pain Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.186  | Pain in Joint Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.187  | Pain on Movement or Joint Pain Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.188  | Non Emergency Ambulance Transport Reason | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.189  | Osteoarthritis Disorder SNOMED CT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.19  | Secondary Erythrocytosis Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.190  | Osteoarthritis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.191  | Osteoarthritis Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.192  | Immunosuppressive Medication RxNorm | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.193  | Medication Supporting Immunosupressive Medication RxNorm | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.194  | Non Emergency Ambulance Transport Qualifying Procedure | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.197  | Turalio | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.198  | Hepatic Medical History | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.2  | Bronchiectasis Disorder ICD10CM | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.20  | Secondary Erythrocytosis Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.21  | Secondary Erythrocytosis Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.22  | Acute or Chronic Heart Failure Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.23  | Acute or Chronic Heart Failure Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.24  | Acute or Chronic Heart Failure Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.25  | Home Oxygen Therapy Qualifying Condition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.26  | Device Use Patient Activity Level | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.27  | Portable Liquid Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.28  | Stationary Liquid Oxygen Therapy Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.29  | Sleep Apnea or Breathing Related Sleep Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.3  | Bronchiectasis Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.30  | Sleep Apnea or Breathing Related Sleep Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.31  | Sleep Apnea or Breathing Related Sleep Disorder | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.32  | Positive Airway Pressure Device | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.33  | Diabetes Mellitus Disorder ICD10CM | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1219.34  | Diabetes Mellitus Disorder SNOMEDCT | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/Val | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.516  | Hyperglycemic Hyperosmolar Nonketotic Syndrome HHNS | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.517  | Hyperglycemic Hyperosmolar Nonketotic Syndrome HHNS | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.518  | Ketoacidosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.519  | Ketoacidosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.52  | Anemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.520  | Ketoacidosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.521  | Diabetic Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.522  | Diabetic Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.523  | Diabetic Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.524  | Diabetic Foot Ulcer | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.525  | Diabetic Foot Ulcer | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.526  | Diabetic Foot Ulcer | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.529  | Charcot Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.53  | Anemia Conditions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.530  | Charcot Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.531  | Charcot Foot | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.533  | Cellulitis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.535  | Diabetic Hand or Diabetic Cheiroarthropathy | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.538  | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.539  | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.540  | Necrobiosis Lipoidica (Skin Lesions) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.541  | Gangrene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.542  | Gangrene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.543  | Gangrene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.544  | Dupuytren's Contracture | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.545  | Dupuytren's Contracture | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.546  | Dupuytren's Contracture | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.547  | Scleroderma or Thick Skin Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.548  | Scleroderma or Thick Skin Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.549  | Scleroderma or Thick Skin Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.554  | Acanthosis Nigricans | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.555  | Acanthosis Nigricans | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.556  | Acanthosis Nigricans | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.557  | Eruptive Xanthomatosis | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.558  | Periodontitis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.559  | Periodontitis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.560  | Periodontitis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.561  | Amputated Limb (Not Traumatic) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.562  | Amputated Limb (Not Traumatic) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.563  | Amputated Limb (Not Traumatic) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.564  | Hypertension, Essential or Primary ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.565  | Hypertension, Essential or Primary SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.567  | Hypertension, Secondary ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.568  | Hypertension, Secondary SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.571  | Hypertension Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.579  | Cardiomyopathy | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.58  | Hypercalcemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.580  | NYHA Heart Failure Functional Classifications | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.581  | American Heart Association Heart Failure Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.582  | Framingham Risk Assessments | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.583  | American College of Cardiology or American Heart Association Ascvd Risk Score (acc/aha Ascvd Risk) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.584  | Atherosclerotic Cardiovascular Disease | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.586  | Gout | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.587  | Psoriatic Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.588  | Reactive Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.59  | Hypercalcemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.590  | Experience of Traumatic Events | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.591  | Cannabis Use | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.592  | Hearing Impairment | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.6  | Chronic Kidney Disease Type or Cause | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.60  | Hypercalcemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.606  | Angina | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.607  | Angina | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.608  | Angina | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.609  | Unstable Angina | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.61  | Hypocalcemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.610  | Unstable Angina | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.611  | Unstable Angina | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.613  | Ischemic Heart Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.614  | Ischemic Heart Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.615  | Left Ventricular Hypertrophy SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.616  | Stroke History | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.618  | Stroke | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.619  | Transient Ischemic Attack | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.62  | Hypocalcemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.620  | Transient Ischemic Attack | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.621  | Transient Ischemic Attack | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.625  | Aneurysm | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.626  | Aneurysm | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.627  | Aneurysm | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.63  | Hypocalcemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.634  | Aortic Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.635  | Aortic Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.636  | Aortic Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.637  | Carotid Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.638  | Carotid Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.639  | Carotid Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.64  | Hyperphosphatemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.640  | Intracranial Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.641  | Intracranial Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.642  | Intracranial Stenosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.643  | Pulmonary Edema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.644  | Pulmonary Edema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.645  | Pulmonary Edema | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.646  | Osteoarthritis (Oa) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.647  | Osteoarthritis (Oa) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.648  | Osteoarthritis (Oa) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.649  | Rheumatoid Arthritis (Ra) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.65  | Hyperphosphatemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.650  | Rheumatoid Arthritis (Ra) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.651  | Rheumatoid Arthritis (Ra) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.652  | Infectious Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.653  | Infectious Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.654  | Infectious Arthritis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.656  | Temporomandibular Disorder Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.658  | Irritable Bowel Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.659  | Irritable Bowel Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.66  | Hyperphosphatemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.660  | Irritable Bowel Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.661  | Neuropathic Pain (Neuralgia) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.662  | Neuropathic Pain (Neuralgia) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.663  | Neuropathic Pain (Neuralgia) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.664  | Neuromas | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.665  | Neuromas | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.666  | Neuromas | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.667  | Phantom Pain | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.668  | Phantom Pain | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.669  | Phantom Pain | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.67  | Hematuria Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.670  | Entrapment Neuropathy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.671  | Entrapment Neuropathy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.672  | Entrapment Neuropathy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.673  | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.674  | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.675  | Myalgic Encephalomyelitis or Chronic Fatigue Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.676  | Psychotic Depression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.677  | Psychotic Depression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.678  | Psychotic Depression | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.679  | Post Partum Depression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.68  | Hematuria Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.680  | Post Partum Depression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.681  | Post Partum Depression | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.682  | Seasonal Affective Disorder | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.683  | Seasonal Affective Disorder | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.684  | Seasonal Affective Disorder | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.685  | Psychological Trauma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.686  | Psychological Trauma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.687  | Psychological Trauma | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.688  | Grief or Loss | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.689  | Grief or Loss | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.69  | Hematuria Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.690  | Grief or Loss | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.691  | Suicide Risk | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.692  | Suicide Risk | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.693  | Suicide Risk | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.694  | Vaping | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.695  | Vaping | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.696  | Vaping | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.697  | Tobacco Use or Exposure | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.699  | Tobacco Use or Exposure | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.70  | Metabolic Acidosis Conditions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.701  | Binge Drinking | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.702  | Binge Drinking | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.703  | Binge Drinking | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.704  | Drug Misuse | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.705  | Drug Misuse | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.706  | Drug Misuse | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.707  | Drug Misuse | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.708  | Sensory Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.709  | Sensory Status | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.71  | Metabolic Acidosis Conditions ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.711  | Fall Risk | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.713  | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.714  | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.715  | Lower Urinary Tract Symptoms (LUTS) From Benign Prostatic Hyperplasia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.716  | Urinary Incontinence | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.717  | Urinary Incontinence | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.718  | Urinary Incontinence | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.719  | Urinary Urgency | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.72  | Metabolic Acidosis Conditions SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.720  | Urinary Urgency | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.721  | Urinary Urgency | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.722  | Urinary Frequency | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.723  | Urinary Frequency | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.724  | Urinary Frequency | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.725  | Nocturia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.726  | Nocturia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.727  | Nocturia | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.728  | Pelvic Organ Prolapse | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.729  | Pelvic Organ Prolapse | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.73  | Hyperlipidemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.730  | Pelvic Organ Prolapse | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.731  | Erectile Dysfunction | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.732  | Erectile Dysfunction | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.733  | Erectile Dysfunction | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.734  | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.735  | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.736  | Interstitial Cystitis or Bladder Pain Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.737  | Recurrent Urinary Tract Infections | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.738  | Recurrent Urinary Tract Infections | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.739  | Recurrent Urinary Tract Infections | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.74  | Hyperlipidemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.740  | Hypertriglyceridemia | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.741  | Hypertriglyceridemia | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.742  | Hypertriglyceridemia | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.743  | Hypothyroidism | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.744  | Hypothyroidism | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.745  | Hypothyroidism | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.746  | Menopause | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.747  | Menopause | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.748  | Menopause | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.749  | Testicular Hypofunction | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.75  | Hyperlipidemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.750  | Testicular Hypofunction | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.751  | Testicular Hypofunction | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.752  | Primary Aldosteronism | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.753  | Primary Aldosteronism | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.754  | Primary Aldosteronism | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.755  | Restless Leg Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.756  | Restless Leg Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.757  | Restless Leg Syndrome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.759  | Claudication | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.76  | Chronic Pain Conditions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.760  | Claudication | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.761  | Claudication | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.762  | Angioedema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.763  | Angioedema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.764  | Angioedema | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.768  | Nonalcoholic Fatty Liver Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.769  | Nonalcoholic Fatty Liver Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.77  | Chronic Pain ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.770  | Nonalcoholic Fatty Liver Disease | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.771  | Thalassemia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.772  | Thalassemia | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.773  | Thalassemia | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.78  | Chronic Pain SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.79  | Arthritis Disorders SCT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.790  | Urine Protein to Creatinine Ratio (UPCR) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.791  | 24 Hour Urine Volume | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.792  | 24 Hour Urine Protein Excretion | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.793  | Total Carbon Dioxide or Bicarbonate in blood, serum or plasma | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.794  | Calcium (Not Corrected for Serum Albumin) in Blood, Plasms, or Serum | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.795  | B Type Natriuretic Peptide [Bnp] in Blood, Serum or Plasma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.797  | N Terminal Pro_B_Type Natriuretic Peptide [Nt_Probnp] in blood, serum or plasma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.799  | Temporomandibular Disorder Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.80  | Arthritis Disorders ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.800  | Temporomandibular Disorder Diagnosis | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.801  | High Sensitivity Troponin | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.804  | Aspartate Transaminase or Alanine Aminotransferase Ratio | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.805  | Alkaline Phosphatase (Alp) in Blood, Serum or Plasma | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.806  | Gamma Glutamyl Transpeptidase (Ggt) in blood, serum or plasma | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.807  | Triiodothyronine in serum or plasma | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.808  | Fasting Blood Glucose | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.809  | Random Blood Glucose Test | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.81  | Arthritis Disorders | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.810  | Uric Acid (Urate) in blood, serum or plasma | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.811  | Aldosterone/Renin Ratio | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.812  | Serum Rheumatoid Factor | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.813  | Blood Ethanol Level | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.814  | Drugs of Abuse Screen in Hair | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.815  | Drugs of Abuse Screen in Urine | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.816  | Drugs of Abuse Screen in Blood | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.817  | Drugs of Abuse Screen in Tissue | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.818  | Drugs of Abuse Screen in Body Fluid | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.819  | Urea Reduction Ratio | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.82  | Preeclampsia Disorders SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.822  | Bowel Sounds | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.823  | Uroflowmetry | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.826  | Gait Quality | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.828  | Balance Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.83  | Preeclampsia Disorders ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.836  | Sit to Stand Ability | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.84  | Preeclampsia Disorders | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.840  | Spinal Cord Compression | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.841  | Spinal Cord Compression | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.842  | Alcohol Use (Revised 2021) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.843  | Alcohol Use (Revised 2021) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.844  | Alcohol Use (Revised 2021) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.845  | Alcohol Use | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.85  | Hyperuricemia Conditions | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.86  | Hyperuricemia Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.864  | Kidney Biopsy Report | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.867  | Skin Biopsy Report | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.868  | Muscle Biopsy Report | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.869  | Gastric Tissue Biopsy Report | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.87  | Hyperuricemia Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.870  | Bone Biopsy Report | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.873  | Echocardiogram | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.88  | Vitamin D Deficiency Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.880  | Spinal or Back CT | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.881  | Chest CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.882  | Abdominal or Pelvic CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.883  | Limb CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.884  | Heart Calcium Score | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.885  | Coronary CT Angiogram | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.886  | Limb CT Angiogram | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.888  | Chest CT Angiogram | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.889  | Head and Neck CT Angiogram | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.89  | Vitamin D Deficiency Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.891  | Gastrointestinal Tract X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.892  | Gallbladder X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.893  | Kidney X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.894  | Abdomen X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.895  | Pelvis X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.896  | Hand X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.897  | Wrist X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.898  | Forearm X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.899  | Elbow X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.90  | Vitamin D Deficiency Conditions | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.900  | Upper Arm X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.901  | Shoulder X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.902  | Upper Extremity X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.903  | Foot X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.904  | Ankle X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.905  | Shin X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.906  | Knee X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.907  | Thigh X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.908  | Hip X Ray | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.909  | Lower Extremity X Ray | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.91  | Alkaline Phosphatase Deficiency Conditions SCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.910  | Abdominal MRI | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.911  | Adrenal Gland MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.912  | Kidney MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.913  | Pancreas MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.915  | Kidney MRA | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.916  | Chest Region MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.917  | Pulmonary MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.918  | Cardiac MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.92  | Alkaline Phosphatase Deficiency Conditions ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.920  | Spine MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.921  | Head and Neck MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.922  | Brain MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.923  | Pelvic Region MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.924  | Knee MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.925  | Foot MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.927  | Shoulder MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.928  | Lower Extremity MRA | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.93  | Alkaline Phosphatase Deficiency Conditions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.930  | Spine X Ray | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.933  | Hip MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.934  | Thigh or Femur MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.935  | Ankle MRI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.936  | Lower Extremity MRI | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.937  | Forearm MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.938  | Elbow MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.939  | Wrist MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.94  | Uremic Pruritus Conditions ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.940  | Hand MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.942  | Upper Extremity MRI | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.943  | Abdominal MRA | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.944  | Chest MRA | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.945  | Upper Extremity MRA | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.947  | Head and Neck MRA | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.948  | Pelvic Region MRA | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.949  | Functional MRI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.95  | Uremic Pruritus Conditions SCT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.951  | Optical Coherence Tomography | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.954  | Bathing or grooming/hygiene (ADL/IADL) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.955  | Dressing (ADL or IADL) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.956  | Toileting (ADL or IADL) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.957  | Transferring (ADL or IADL) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.958  | Walking or ambulation/locomotion (ADL/IADL) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.96  | Uremic Pruritus Conditions | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.960  | Domestic Duties or Household Tasks (ADL/IADL) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.961  | Telephone Use (ADL or IADL) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.962  | Bed Mobility (ADL or IADL) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.963  | Stair Use (ADL or IADL) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.964  | Medication Management (ADL or IADL) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.967  | Electromyography | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.968  | Electroencephalogram | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.969  | Exercise Stress Test | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.97  | Insomnia Disorders | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.976  | Sleep Duration, Device | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.977  | Steps Per Time, Device | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.978  | Physical Activity Level, Device | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.979  | Cognitive Function Clinician Interpretation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.98  | Insomnia Disorders ICD10 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.987  | Psychosis | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.99  | Insomnia Disorders SCT | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.991  | Suicidal Ideation and Behaviors | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.994  | Sleep Duration | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.996  | Pain Intensity or Severity | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1222.997  | Pain Quality | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.4  | Glaucoma ICD10 | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1225.5  | Glaucoma SNOMED | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.1  | Scleritis | active | 2021-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.2  | Scleritis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1226.3  | Scleritis | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.1  | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.2  | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Non Diagnostic or Non CT | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.3  | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography Nuclear Medicine With CT | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.4  | Excessive Radiation Dose or Inadequate Image Quality for Diagnostic Computed Tomography CT Without Specified Body Region | active | 2021-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.6  | Outpatient Encounter Locations | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1228.7  | Outpatient Activity Codes | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.6  | Anaphylaxis, ICD10CM codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.60  | Guillain Barre Syndrome, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.61  | Febrile seizure, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.62  | Encephalomyelitis and encephalitis, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.63  | Disseminated Intravascular Coagulation, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.64  | Deep Vein Thrombosis, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.65  | Bells Palsy, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.66  | Appendicitis, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.67  | Anaphylaxis, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.68  | Acute Myocardial Infarction, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.69  | Multisystem Inflammatory Syndrome, SNOMED codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.7  | Anaphylaxis, SNOMED codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.70  | Multisystem Inflammatory Syndrome, diagnosis codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.71  | Transfusion CPT codes for exposure identification | active | 2021-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.72  | Transfusion ICD9 codes for exposure identification | active | 2021-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.73  | Transfusion ICD10PCS codes for exposure identification | active | 2021-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.74  | Transfusion CPT, ICD9, ICD10PCS codes for exposure identification | active | 2021-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.75  | COVID19 vaccine ICD10PCS codes for exposure identification | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.8  | Appendicitis, SNOMED codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1234.9  | Appendicitis, ICD10CM codes for AE reporting | active | 2021-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.1  | Test Diabetes codes | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.100  | Cardiomyopathy Hypertrophic Condition | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.12  | Metabolic Syndrome LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.15  | MetabolicSyndromeCondition | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.16  | Annual Physical ICD9 CN5 | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.164  | Diabetic Retinal Screening HD CPT for Tax Pair | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.165  | Optometrist and Ophthalmologist Taxonomy HD Taxonomy | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.167  | End Stage Renal Disease (ESRD)_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.168  | End Stage Renal Disease (ESRD)_HD_ICD9 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.169  | End Stage Renal Disease (ESRD)_HD_ICD10 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.17  | Annual Physical ICD10 CN5 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.170  | End Stage Renal Disease (ESRD)_HD_HCPCS | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.171  | End Stage Renal Disease (ESRD)_HD_LOINC | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.172  | End Stage Renal Disease (ESRD)_HD_Clinical Condition Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.173  | Systolic Blood Pressure_HD_SNOMED | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.174  | Systolic Blood Pressure_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.175  | Systolic Blood Pressure_HD_LOINC | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.176  | Systolic Blood Pressure_HD | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.177  | Diastolic Blood Pressure_HD_SNOMED | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.178  | Diastolic Blood Pressure_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.179  | Diastolic Blood Pressure_HD_LOINC | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.18  | Annual Physical SNOMED CN5 | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.180  | Diastolic Blood Pressure_HD | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.181  | Remote Blood Pressure_HD_SNOMED | active | 2023-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.182  | Remote Blood Pressure_HD | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.183  | Remote Blood Pressure_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.184  | Acute Inpatient_CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.185  | Acute Inpatient_CN_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.186  | Acute Inpatient_HD_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.187  | ED Visit_CN_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.188  | ED Visit_CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.19  | Annual Physical Taxonomy CN5 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.190  | Pregnancy_HD_Grouping | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.191  | Pregnancy_CN_HD_SNOMED | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.192  | Pregnancy_CN_HD_ICD10 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.193  | ED Visit_HD_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.194  | Lipid Panel_Event_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.195  | Lipid Panel_Event_HCPCS | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.196  | Lipid Panel_Event_LOINC | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.197  | Lipid Panel_Event_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.198  | Lipid Panel_Event_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.199  | Unknown Glucose_Event_ICD9 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.20  | Annual Physical CN5 | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.200  | Unknown Glucose_Event_ICD10 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.201  | Unknown Glucose_Event_LOINC | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.202  | Unknown Glucose_Event_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.203  | Unknown Glucose_Event_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.204  | Unknown Glucose_Lab_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.205  | Bone Marrow Transplant CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.206  | Bone Marrow Transplant CN_HD_ICD10 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.207  | Bone Marrow Transplant_HD_CN_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.208  | Immunocompromising Conditions CN_HD_ICD9 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.209  | Immunocompromising Conditions CN_HD_ICD10PCS | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.21  | Annual Physical CPT CN5 | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.210  | Immunocompromising Conditions CN_HD_ICD10CM | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.211  | Immunocompromising Conditions_HD_CN_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.212  | Immunocompromising Conditions CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.213  | Cerebrospinal Fluid Leak CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.214  | Cerebrospinal Fluid Leak CN_HD_ICD10 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.215  | Cerebrospinal Fluid Leak_HD_CN_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.216  | Anatomic or Functional Asplenia CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.217  | Anatomic or Functional Asplenia CN_HD_ICD9 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.218  | Anatomic or Functional Asplenia CN_HD_ICD10 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.219  | Anatomic or Functional Asplenia_HD_CN_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.22  | Annual Physical HCPCS CN5 | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.220  | Sickle cell Anemia and HB S Disease CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.221  | Sickle cell Anemia and HB S Disease CN_HD_ICD10 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.222  | Sickle cell Anemia and HB S Disease_HD_CN_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.223  | Pneumococcal Vaccine CN_HD_SNOMED | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.224  | Pneumococcal Vaccine CN_HD_HCPCS | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.225  | Pneumococcal Vaccine CN_HD_CVX | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.226  | Pneumococcal Vaccine CN_HD_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.227  | Pneumococcal Vaccine_HD_CN_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.228  | Influenza Vaccine CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.229  | Influenza Vaccine CN_HD_HCPCS | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.23  | Annual Physical CPT for Tax Pair CN5 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.230  | Influenza Vaccine CN_HD_CVX | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.231  | Influenza Vaccine CN_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.232  | Influenza Vaccine_HD_CN_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.233  | Cochlear Implant CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.234  | Cochlear Implant CN_HD_ICD10 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.235  | Cochlear Implant CN_HD_HCPCS | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.236  | Cochlear Implant CN_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.237  | Cochlear Implant_HD_CN_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.238  | Chemotherapy CN_HD_SNOMED | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.239  | Chemotherapy CN_HD_ICD10 | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.24  | Annual Physical ICD9 for Tax Pair CN5 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.240  | Chemotherapy CN_HD_CPT | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.241  | Chemotherapy_HD_CN_Grouping | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.244  | Fasting Blood Glucose_Lab_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.245  | Chronic Heart Failure (CHF)_ICD9 | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.246  | Chronic Heart Failure (CHF)_ICD10 | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.251  | Asthma_LOINC | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.253  | Asthma_Clinical Condition Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.254  | Pregnancy Loss_HD_SNOMED | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.255  | Pregnancy Loss_HD_ICD10 | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.257  | Pregnancy Loss_HD_Clinical Condition Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.258  | Heart Failure (CHF)_ICD9 | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.259  | Heart Failure (CHF)_ICD10 | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.260  | Heart Failure (CHF)_SNOMED | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.261  | Heart Failure (CHF)_HCPCS | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.262  | Heart Failure (CHF)_LOINC | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.263  | Heart Failure (CHF)_CPT | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.264  | Heart Failure (CHF)_RxNorm | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.265  | Heart Failure (CHF)_Clinical Condition Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.270  | Triglyceride_Lab_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.274  | Total Cholesterol_CPT | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.275  | Total Cholesterol_Lab_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.276  | LDL_SNOMED | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.280  | LDL_Lab_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.284  | HDL_LOINC | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.285  | HDL_Lab_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.286  | Colectomy_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.288  | Colectomy_ICD9 | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.29  | Hospice Exclusions Grouping | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.290  | Colectomy_Event_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.291  | CT Colonography_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.292  | CT Colonography_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.294  | CT Colonography_Event_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.295  | FIT DNA_LOINC | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.296  | FIT DNA_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.297  | FIT DNA_HCPCS | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.298  | FIT DNA_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.299  | FIT DNA Test_Lab_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.30  | Annual Physical Codes for Tax Pair CN5 | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.300  | Sigmoidoscopy_CPT | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.302  | Sigmoidoscopy_ICD9 | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.303  | Sigmoidoscopy_SNOMED | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.304  | Sigmoidoscopy_Event_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.305  | Colonoscopy_CPT | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.306  | Colonoscopy_HCPCS | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.307  | Colonoscopy_ICD9 | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.308  | Colonoscopy_SNOMED | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.309  | Colonoscopy_Event_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.310  | FOBT Lab_CPT | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.311  | FOBT Lab_HCPCS | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.312  | FOBT Lab_LOINC | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.313  | FOBT Lab_SNOMED | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.314  | FOBT Lab Test_Lab_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.315  | Colorectal Cancer_HD_ICD10 | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.316  | Colorectal Cancer_HD_ICD9 | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.317  | Colorectal Cancer_HD_SNOMED | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.318  | Colorectal Cancer_HD_Grouping | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.319  | Absence of Cervix Diagnosis_HD_ICD10 | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.320  | Absence of Cervix Diagnosis_HD_ICD9 | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.321  | Absence of Cervix Diagnosis_HD_SNOMED | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.322  | Absence of Cervix Diagnosis_HD_Grouping | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.323  | Hysterectomy With No Residual Cervix_HD_CPT | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.324  | Hysterectomy With No Residual Cervix_HD_ICD10 | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.325  | Hysterectomy With No Residual Cervix_HD_ICD9 | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.326  | Hysterectomy With No Residual Cervix_HD_SNOMED | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.327  | Hysterectomy With No Residual Cervix_HD_Grouping | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.328  | High Risk HPV Test_HD_CPT | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.329  | High Risk HPV Test_HD_HCPCS | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.330  | High Risk HPV Test_HD_LOINC | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.331  | High Risk HPV Test_HD_SNOMED | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.332  | High Risk HPV Test_HD_Grouping | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.333  | Cervical Cytology_HD_CPT | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.334  | Cervical Cytology_HD_HCPCS | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.335  | Cervical Cytology_HD_LOINC | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.336  | Cervical Cytology_HD_SNOMED | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.337  | Cervical Cytology_HD_Grouping | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.338  | AFib (Atrial Fibrillation)_ICD9 | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.339  | AFib (Atrial Fibrillation)_ICD10 | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.340  | AFib (Atrial Fibrillation)_SNOMED | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.341  | AFib (Atrial Fibrillation)_LOINC | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.342  | AFib (Atrial Fibrillation)_RxNORM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.343  | AFib (Atrial Fibrillation)_CPT | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.344  | AFib (Atrial Fibrillation)_Clinical Condition Grouping | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.345  | COVID19 Vaccine_CPT | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.346  | COVID19 Vaccine_HCPCS | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.348  | COVID19 Vaccine_RxNorm | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.349  | COVID19 Vaccine_CVX | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.350  | COVID19 Vaccine_Event Clinical Grouping | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.351  | Coronary Artery Disease (CAD)_ICD9 | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.352  | Coronary Artery Disease (CAD)_ICD10PCS | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.353  | Coronary Artery Disease (CAD)_ICD10CM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.354  | Coronary Artery Disease (CAD)_CPT | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.355  | Coronary Artery Disease (CAD)_HCPCS | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.356  | Coronary Artery Disease (CAD)_LOINC | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.357  | Coronary Artery Disease (CAD)_SNOMED | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.358  | Coronary Artery Disease (CAD)_CUI_UMLS | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.359  | Coronary Artery Disease (CAD)_Clinical Condition Grouping | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.360  | Allergy List_SNOMED | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.361  | Allergy List_ICD10 | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.362  | Allergy List_Clinical Grouping Event | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.363  | Statin Use_RxNorm | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.364  | Other Revascularization_SNOMED | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.365  | Other Revascularization_CPT | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.366  | Other Revascularization_Grouping | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.367  | Ischemic Vascular Disease (IVD)_SNOMED | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.368  | Ischemic Vascular Disease (IVD)_ICD10 | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.369  | Ischemic Vascular Disease (IVD)_Grouping | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.370  | Muscular Pain and Disease_SNOMED | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.371  | Muscular Pain and Disease_ICD10 | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.372  | Muscular Pain and Disease_Grouping | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.373  | Cirrhosis_SNOMED | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.374  | Cirrhosis_ICD10 | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.375  | Cirrhosis_Grouping | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.376  | IVF_SNOMED | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.377  | IVF_HCPCS | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.378  | IVF_Grouping | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.379  | Estrogen Agonists Medications_RXNORM | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.382  | Pre_Hypertension (Pre_HTN)_Clinical Condition Grouping | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.384  | Family History Hypertension (HTN)_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.385  | Family History Hypertension (HTN)_Clinical Condition Grouping | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.386  | Obesity_Condition_UMLS | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.387  | Podiatry_Taxonomy | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.388  | Cardiology _Taxonomy | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.393  | BMI >=40_Event_Clinical Condition Grouping | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.400  | Smoker Status_Event_Clinical Condition Grouping | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.401  | First Trimester_ICD10 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.402  | First Trimester_SNOMED | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.403  | First Trimester_LOINC | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.404  | First Trimester_CPT | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.405  | First Trimester_UMLS CUI | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.406  | First Trimester_Clinical Grouping Event | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.408  | Birth Event_ICD10 | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.409  | Birth Event_SNOMED | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.413  | Birth Event_Clinical Grouping Event | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.414  | Obesity_Condition_SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.415  | Obesity_Condition_ICD10 | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.416  | Obesity_Condition_ICD9 | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.417  | Obesity_Clinical Grouping Condition | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.418  | Pre_Hypertension (Pre_HTN)_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.419  | Pre_Hypertension (Pre_HTN)_ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.420  | Pre_Hypertension (Pre_HTN)_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.424  | BMI >=30_Event_Clinical Condition Grouping | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.427  | Obesity_Condition_LOINC | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.428  | Vitals Body Height LOINC | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.429  | Vitals Body Height SnoMed | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.430  | Vitals Body Height | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.431  | bwell_Vital_Blood Glucose_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.432  | Anxiety_Clinical Grouping Condition_ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.433  | Anxiety_Clinical Grouping Condition_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.434  | Anxiety_Clinical Grouping Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.435  | Anxiety_Clinical Grouping Condition_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.436  | Anxiety_Clinical Grouping Condition | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.437  | bwell_Vital_Blood Oxygen_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.438  | bwell_Vital_Systolic Blood Pressure_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.439  | bwell_Vital_Diastolic Blood Pressure_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.440  | bwell_Vital_Heart Rate_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.441  | bwell_Vital_BMI_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.442  | bwell_Vital_Body Fat_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.443  | bwell_Vital_Body Temperature_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.444  | bwell_Vital_Body Height_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.445  | bwell_Vital_Body Weight_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.446  | bwell_Vital_Respiratory Rate_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.447  | bwell_Vital_Waist Circumference_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.448  | bwell_Vital_Blood Glucose_Clinical Grouping Lab | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.449  | bwell_Vital_Blood Oxygen_Clinical Grouping Event | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.450  | bwell_Vital_Systolic Blood Pressure_Clinical Grouping Event | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.451  | bwell_Vital_Diastolic Blood Pressure_Clinical Grouping Event | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.452  | bwell_Vital_Heart Rate_Clinical Grouping Event | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.453  | bwell_Vital_BMI_Clinical Grouping Event | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.454  | bwell_Vital_Body Fat_Clinical Grouping Event | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.455  | bwell_Vital_Body Temperature_Clinical Grouping Event | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.456  | bwell_Vital_Body Height_Clinical Grouping Event | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.457  | bwell_Vital_Body Weight_Clinical Grouping Event | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.458  | bwell_Vital_Respiratory Rate_Clinical Grouping Event | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.459  | bwell_Vital_Waist Circumference_Clinical Grouping Event | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.460  | Pregnancy_CN_HD_LOINC | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.461  | Pregnancy_CN_HD_CPT | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.462  | Pregnancy_CN_HD_UMLS | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.463  | Second Trimester_ICD10 | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.464  | Second Trimester_SNOMED | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.465  | Second Trimester_Clinical Grouping Event | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.466  | Third Trimester_SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.467  | Third Trimester_ICD10 | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.468  | Third Trimester_Clinical Grouping Event | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.469  | Pregnancy Due Date_LOINC | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.470  | Second Trimester_LOINC | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.472  | OGTT_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.473  | OGTT_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.475  | OGTT_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.476  | OGTT_Grouping | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.477  | Second Trimester_CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.479  | Prostate Cancer Screening_HD_ICD9 | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.482  | Prostate Cancer Screening_HD_Grouping | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.484  | Prostate Dysplasia_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.486  | Prostate Dysplasia_Grouping | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.487  | Prostectomy_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.488  | Prostectomy_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.490  | Prostectomy_Grouping | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.494  | PSA Testing _LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.495  | PSA Testing_Grouping | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.496  | Active Pregnancy_CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.497  | Active Pregnancy_ICD10 | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.498  | Active Pregnancy_LOINC | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.499  | Active Pregnancy_SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.5  | ADD/ADHD Condition | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.500  | Active Pregnancy_Clinical Grouping Event | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.501  | Abnormal PSA Testing _SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.502  | Prediabetes_Clinical Grouping Condition_ICD10 | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.503  | Prediabetes_Clinical Grouping Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.504  | Prediabetes_Clinical Grouping Condition | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.505  | Third Trimester_CPT | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.506  | Third Trimester_LOINC | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.508  | bwell_Vital_Waist Circumference_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.509  | bwell_Vital_Blood Oxygen_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.510  | bwell_Vital_Body Temperature_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.511  | bwell_Vital_Diastolic Blood Pressure_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.512  | bwell_Vital_Systolic Blood Pressure_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.513  | bwell_Vital_Systolic_and_Diastolic Blood Pressure_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.514  | bwell_Vital_Systolic_and_Diastolic Blood Pressure_Clinical Grouping Event | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.515  | bwell_Vital_Heart Rate_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.516  | bwell_Vital_Respiratory Rate_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.517  | Lupus_Clinical_Condition_ICD10 | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.519  | Lupus_Clinical_Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.520  | Lupus_Clinical Condition Grouping | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.523  | UTI_Clinical_Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.524  | UTI_Clinical Condition Grouping | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.525  | Postpartum_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.526  | Postpartum_HCPCS | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.527  | Postpartum_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.528  | Postpartum_ICD9CM | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.529  | Postpartum_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.530  | Postpartum_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.531  | Postpartum_Clinical Grouping Event | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.532  | bwell_Vital_Head Circumference_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.533  | bwell_Vital_Head Circumference_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.534  | bwell_Vital_Head Circumference_Clinical Grouping Event | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.535  | bwell_Vital_Body Surface Area_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.536  | bwell_Vital_Body Surface Area_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.537  | bwell_Vital_Body Surface Area_Clinical Grouping Event | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.538  | bwell_Vital_Vital Signs Panel_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.539  | bwell_Vital_Vital Signs Panel_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.540  | bwell_Vital_Vital Signs Panel_Clinical Grouping Event | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.541  | bwell_Vital_Blood Pressure Panel_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.542  | bwell_Vital_Blood Pressure Panel_Clinical Grouping Event | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.543  | Depression_Clinical Grouping Condition_CPT | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.544  | Depression_Clinical Grouping Condition_HCPCS | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.545  | Depression_Clinical Grouping Condition_ICD10 | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.546  | Depression_Clinical Grouping Condition_ICD9 | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.547  | Depression_Clinical Grouping Condition_LOINC | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.548  | Depression_Clinical Grouping Condition_SNOMED | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.549  | Depression_Clinical Grouping Condition | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.550  | MI (Myocardial Infarction)_Clinical Grouping Condition_ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.551  | MI (Myocardial Infarction)_Clinical Grouping Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.552  | MI (Myocardial Infarction)_Clinical Grouping Condition_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.553  | MI (Myocardial Infarction)_Clinical Grouping Condition | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.554  | CABG_Clinical Grouping Condition_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.555  | CABG_Clinical Grouping Condition_HCPCS | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.556  | CABG_Clinical Grouping Condition_ICD10PCS | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.557  | CABG_Clinical Grouping Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.558  | CABG_Clinical Grouping Condition | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.559  | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.56  | Diabetic Retinal Screening HD CPT | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.560  | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_HCPCS | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.561  | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_ICD10PCS | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.562  | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_ICD9PCS | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.563  | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.564  | PCI (Percutaneous Coronary Intervention)_Clinical Grouping Condition | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.565  | Essential HTN_HD_Clinical Grouping Condition_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.566  | Essential HTN_HD_Clinical Grouping Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.567  | Essential HTN_HD_Clinical Grouping Condition | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.568  | Total and Partial Neph_HD_Clinical Grouping Condition_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.569  | Total and Partial Neph_HD_Clinical Grouping Condition_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.570  | Total and Partial Neph_HD_Clinical Grouping Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.571  | Total and Partial Neph_HD_Clinical Grouping Condition | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.572  | Kid Trans and Hx_HD_Clinical Grouping Condition_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.573  | Kid Trans and Hx_HD_Clinical Grouping Condition_HCPCS | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.574  | Kid Trans and Hx_HD_Clinical Grouping Condition_ICD10CM | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.575  | Kid Trans and Hx_HD_Clinical Grouping Condition_ICD10PCS | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.576  | Kid Trans and Hx_HD_Clinical Grouping Condition_ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.577  | Kid Trans and Hx_HD_Clinical Grouping Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.578  | Kid Trans and Hx_HD_Clinical Grouping Condition | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.579  | HbA1c Level Less Than 8.0_HD_Clinical Grouping Condition_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.580  | HbA1c Level Less Than 8.0_HD_Clinical Grouping Condition | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.581  | Systolic Less than 140_HD_Clinical Grouping Event_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.582  | Diastolic Less than 90_HD_Clinical Grouping Event_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.583  | Systolic Less than 140_HD_Clinical Grouping Event | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.584  | Diastolic Less than 90_HD_Clinical Grouping Event | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.585  | COPD_Clinical_Grouping_Condition_ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.586  | COPD_Clinical_Grouping_Condition_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.587  | COPD_Clinical_Grouping_Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.588  | COPD_Clinical Condition Grouping | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.589  | Polypharmacy_Clinical_Grouping_Condition_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.590  | Polypharmacy_Clinical_Grouping_Condition_ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.591  | Polypharmacy_Clinical_Grouping_Condition_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.592  | Polypharmacy_Clinical_Grouping_Condition_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.593  | Polypharmacy_Clinical Condition Grouping | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.595  | Thyroid Cancer_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.596  | Thyroid Cancer_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.597  | Thyroid Cancer_Grouping | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.598  | Allergy Iodine_SNOMED | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.599  | Allergy to contrast_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.600  | Allergy to contrast_ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.601  | Allergy to contrast_Grouping | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.602  | Contrast induced nephropathy_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.603  | Contrast induced nephropathy_ICD10 | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.604  | Contrast induced nephropathy_Grouping | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.605  | Systolic Blood Pressure_Compliant | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.606  | Diastolic Blood Pressure_Compliant | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.607  | Diastolic Blood Pressure_Compliant_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.608  | Systolic Blood Pressure_Compliant_CPT | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.609  | bwell Systolic Blood Pressure Vitals_UI_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.610  | bwell Systolic Blood Pressure Vitals_UI_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.611  | bwell Diastolic Blood Pressure Vitals_UI_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.612  | bwell Diastolic Blood Pressure Vitals_UI_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.613  | bwell Combo Blood Pressure Vitals_UI_LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.614  | bwell Combo Blood Pressure Vitals_UI_SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.615  | bwell Systolic Blood Pressure_UI | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.616  | bwell Diastolic Blood Pressure_UI | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.617  | bwell Combo Blood Pressure_UI | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.618  | b.well Herpes Zoster Vaccine CN_HD | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.619  | b.well Herpes Zoster Vaccine CN_HD_SNOMED | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.620  | b.well Herpes Zoster Vaccine CN_HD_CVX | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.621  | b.well Herpes Zoster Vaccine CN_HD_CPT | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.622  | b.well Herpes Zoster Vaccine CN_HD_2dose | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.623  | b.well Herpes Zoster Vaccine CN_HD_2dose_CPT | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.624  | b.well Herpes Zoster Vaccine CN_HD_2dose_CVX | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.625  | b.well Herpes Zoster Vaccine CN_HD_2dose_SNOMED | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.626  | b.well Herpes Zoster Vaccine CN_HD_Exclusions | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.627  | b.well Herpes Zoster Vaccine CN_HD_Exclusions_SNOMED | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.628  | b.well Adult RSV Vaccine CN_CVX | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.629  | b.well Adult RSV Vaccine CN_CPT | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.630  | b.well Adult RSV Vaccine CN_HCPCS | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.631  | b.well Adult RSV Vaccine CN_SNOMED | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.633  | Lp(a) Test_SNOMED | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.634  | Lp(a) Test_LOINC | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.635  | LP(a) Test_ICD | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.636  | Lp(a) Test_CPT | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.637  | LP(a) Test | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.638  | b.well Adult Tetanus Vaccine CN | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.639  | BWellAdultTetanusVaccineCN_SNOMED | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.640  | b.well Adult Tetanus Vaccine CN_CPT | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.641  | b.well Adult Tetanus Vaccine CN_CVX | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.642  | b.well Adult Tetanus Vaccine CN_Exclusions_SNOMED | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.643  | b.well Adult Tetanus Vaccine CN_Exclusions | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.644  | BWellAdultTetanusVaccineCN_RxNorm | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.645  | Pneumococcal Vaccine HD_CN_ Allergy | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.646  | bwell COVID Vaccine CN_Allergy | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.647  | bwell Covid Vaccine CN_Allergy_SNOMED | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.648  | bwell COVID Vaccine CN_Met | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.9  | Metabolic Syndrome ICD10 | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.91  | Cardiomyopathy Dilated ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.92  | Cardiomyopathy Dilated ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.93  | Cardiomyopathy Dilated SNOMED | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.94  | Cardiomyopathy Dilated Condition | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.95  | Cardiomyopathy Dilated LOINC | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.96  | Cardiomyopathy Hypertrophic ICD9 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.97  | Cardiomyopathy Hypertrophic ICD10 | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.98  | Cardiomyopathy Hypertrophic SNOMED | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1235.99  | Cardiomyopathy Hypertrophic LOINC | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.12  | SNOMEDFindingValuesQualifierValue | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.13  | SNOMED Organism from LOINC Answer List | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.18  | Medication Prescribable Brand Name | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.2  | SNOMED Organisms | active | 2021-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1237.22  | Medicinal Ingredients RXNORM | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.1  | Mental Status Observation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.10  | Other Unknown Nulls | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.11  | Sexual Orientation Including nulls and Data Absent Reason | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.12  | Pregnancy Status Observation | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.2  | No Healthcare Agent Included Reason | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.3  | Sex | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.4  | Asked Declined Data Absent Reason | active | 2023-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.5  | Act Encounter Codes | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.6  | Completed or Nullified Act Status | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.7  | Data Absent Reason Types of Unknown | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1240.8  | Medication Adherence | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.2  | Sickle Cell Disease | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1242.4  | Depression | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.1  | Food Insecurity Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.100  | Intimate Partner Violence Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.101  | Less Than High School Education Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.102  | Less Than High School Education Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.103  | Less Than High School Education Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.106  | Transportation Insecurity Interventions SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.107  | Financial Insecurity Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.108  | Financial Insecurity Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.109  | Financial Insecurity Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.11  | Food Insecurity Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.110  | Medical Cost Burden Goals SNOMED CT | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.111  | Health Insurance Coverage Status Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.112  | Health Literacy Diagnoses SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.113  | Health Literacy Diagnoses ICD10CM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.114  | Health Literacy Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.115  | Health Literacy Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.116  | Health Literacy Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.117  | Health Literacy Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.118  | Health Literacy Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.119  | Health Literacy Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.120  | Medical Cost Burden Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.121  | Health Insurance Coverage Status Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.122  | Medical Cost Burden Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.123  | Medical Cost Burden Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.124  | Health Insurance Coverage Status Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.125  | Health Insurance Coverage Status Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.126  | Social Determinants of Health Screening Assessments | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.127  | Food Insecurity Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.128  | Transportation Insecurity Screening Assessments | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.129  | Homelessness Screening Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.13  | Homelessness Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.130  | Housing Instability Screening Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.131  | Inadequate Housing Screening Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.132  | Less Than High School Education Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.133  | Unemployment Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.134  | Veteran Status Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.135  | Social Connection Screening Assessments | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.136  | Stress Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.137  | Cognitive disorder Diagnosis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.138  | Financial Insecurity Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.139  | Material Hardship Screening Assessments | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.14  | Homelessness Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.140  | Intimate Partner Violence Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.141  | Health Literacy Screening Assessments | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.142  | Medical Cost Burden Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.143  | Health Insurance Coverage Status Screening Assessments | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.144  | Elder Abuse Screening Assessments | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.145  | Less Than High School Education Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.146  | Financial Insecurity Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.147  | Health Insurance Coverage Status Diagnoses ICD10CM | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.148  | Health Insurance Coverage Status Diagnoses | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.149  | Health Insurance Coverage Status Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.15  | Food Insecurity Interventions CPT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.150  | Material Hardship Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.151  | Medical Cost Burden Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.152  | Medical Cost Burden Diagnoses SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.153  | Medical Cost Burden Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.154  | Medical Cost Burden Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.157  | Transportation Insecurity Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.158  | Homelessness Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.159  | Homelessness Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.16  | Food Insecurity Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.160  | Housing Instability Goals SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.161  | Housing Instability Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.162  | Transportation Insecurity Goals SNOMED CT | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.163  | Transportation Insecurity Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.164  | Veteran Status Interventions SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.167  | Inadequate Housing Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.168  | Material Hardship Screening Assessments Questions | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.169  | Stress Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.17  | Food Insecurity Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.170  | Transportation Insecurity Screening Assessments Questions | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.171  | Unemployment Screening Assessments Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.172  | Veteran Status Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.173  | Financial Insecurity Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.174  | Food Insecurity Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.175  | Health Literacy Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.176  | Homelessness Screening Assessments Answers | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.177  | Housing Instability Screening Assessments Answers | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.178  | Inadequate Housing Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.179  | Less Than High School Education Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.18  | Homelessness Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.180  | Material Hardship Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.181  | Stress Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.182  | Transportation Insecurity Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.183  | Unemployment Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.184  | Veteran Status Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.185  | Health Insurance Coverage Status Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.186  | Health Insurance Coverage Status Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.187  | Medical Cost Burden Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.188  | Medical Cost Burden Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.189  | Elder Abuse Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.19  | Homelessness Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.190  | Elder Abuse Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.191  | Elder Abuse Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.192  | Veteran Status Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.193  | Financial Insecurity Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.194  | Food Insecurity Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.195  | Health Literacy Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.196  | Homelessness Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.197  | Housing Instability Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.198  | Intimate Partner Violence Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.199  | Less Than High School Education Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.20  | Homelessness Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.200  | Material Hardship Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.201  | Medical Cost Burden Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.202  | Social Connection Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.203  | Stress Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.204  | Transportation Insecurity Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.205  | Unemployment Screening Assessments And Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.206  | Social Determinants of Health Screening Assessments And Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.207  | Social Determinants of Health Screening Assessments Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.208  | Social Determinants of Health Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.209  | Intimate Partner Violence Screening Assessments Answers | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.21  | Homelessness Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.210  | Social Connection Screening Assessments Answers | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.211  | Intimate Partner Violence Screening Assessments Questions | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.212  | Social Connection Screening Assessments Questions | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.213  | Health Insurance Coverage Status Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.214  | Veteran Status Goals | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.215  | Veteran Status Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.217  | Digital Literacy Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.218  | Digital Literacy Diagnoses ICD10CM | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.219  | Digital Literacy Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.22  | Housing Instability Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.220  | Digital Literacy Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.224  | Digital Literacy Diagnoses | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.225  | Digital Literacy Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.226  | Digital Literacy Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.227  | Digital Literacy Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.229  | Digital Access Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.23  | Housing Instability Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.230  | Digital Access Diagnoses ICD10CM | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.231  | Digital Access Diagnoses | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.232  | Digital Access Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.233  | Digital Access Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.234  | Digital Access Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.235  | Digital Access Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.236  | Digital Access Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.237  | Digital Access Screening Assessments | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.238  | Digital Access Screening Assessments Questions | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.239  | Digital Access Screening Assessments Answers | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.24  | Housing Instability Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.240  | Digital Access Screening Assessments And Questions | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.241  | Utility Insecurity Diagnoses SNOMED CT | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.242  | Utility Insecurity Diagnoses ICD10CM | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.243  | Utility Insecurity Diagnoses | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.244  | Utility Insecurity Goals SNOMED CT | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.245  | Utility Insecurity Goals | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.246  | Utility Insecurity Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.247  | Utility Insecurity Procedures | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.248  | Utility Insecurity Screening Assessments | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.249  | Utility Insecurity Screening Assessments Questions | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.25  | Transportation Insecurity Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.250  | Utility Insecurity Screening Assessments Answers | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.251  | Utility Insecurity Screening Assessments And Questions | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.252  | Utility Insecurity Service Requests | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.253  | Social Determinants of Health General Interventions HCPCS | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.254  | Incarceration Status Diagnoses ICD10CM | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.255  | Incarceration Status Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.256  | Incarceration Status Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.257  | Incarceration Status Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.258  | Incarceration Status Diagnoses | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.259  | Incarceration Status Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.26  | Transportation Insecurity Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.260  | Incarceration Status Procedures | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.261  | Incarceration Status Service Requests | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.262  | Language Access Diagnoses | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.263  | Language Access Diagnoses ICD10CM | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.264  | Language Access Diagnoses SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.265  | Language Access Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.266  | Language Access Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.267  | Language Access Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.268  | Language Access Procedures | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.269  | Language Access Service Requests | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.27  | Transportation Insecurity Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.270  | Language Access Screening Assessments | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.271  | Language Access Screening Assessments Answers | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.272  | Language Access Screening Assessments Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.273  | Language Access Screening Assessments And Questions | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.28  | Transportation Insecurity Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.29  | Financial Insecurity Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.3  | Food Insecurity Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.30  | Financial Insecurity Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.31  | Financial Insecurity Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.32  | Financial Insecurity Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.33  | Material Hardship Diagnoses ICD10CM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.34  | Material Hardship Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.35  | Material Hardship Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.36  | Material Hardship Goals SNOMED CT | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.37  | Material Hardship Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.38  | Material Hardship Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.39  | Material Hardship Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.4  | Food Insecurity Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.40  | Unemployment Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.41  | Unemployment Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.42  | Unemployment Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.43  | Housing Instability Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.44  | Housing Instability Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.45  | Housing Instability Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.46  | Inadequate Housing Diagnoses SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.47  | Inadequate Housing Diagnoses ICD10CM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.48  | Inadequate Housing Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.49  | Inadequate Housing Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.5  | Social Determinants of Health General Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.50  | Inadequate Housing Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.51  | Inadequate Housing Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.52  | Inadequate Housing Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.53  | Inadequate Housing Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.54  | Less Than High School Education Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.55  | Less Than High School Education Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.56  | Less Than High School Education Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.57  | Less Than High School Education Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.58  | Unemployment Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.59  | Unemployment Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.6  | Food Insecurity Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.60  | Unemployment Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.61  | Elder Abuse Diagnoses ICD10CM | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.62  | Elder Abuse Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.63  | Elder Abuse Diagnoses | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.64  | Elder Abuse Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.65  | Elder Abuse Goals | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.66  | Elder Abuse Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.67  | Elder Abuse Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.68  | Elder Abuse Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.69  | Unemployment Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.7  | Food Insecurity Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.70  | Unemployment Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.71  | Social Determinants of Health Goals | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.72  | Stress Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.73  | Stress Interventions SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.74  | Stress Diagnoses ICD10CM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.75  | Stress Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.76  | Veteran Status Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.77  | Veteran Status Diagnoses ICD10CM | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.78  | Veteran Status Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.79  | Social Connection Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.8  | Social Determinants of Health General Interventions CPT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.80  | Social Connection Diagnoses ICD10CM | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.81  | Social Connection Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.82  | Intimate Partner Violence Diagnoses SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.83  | Intimate Partner Violence Diagnoses ICD10CM | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.84  | Intimate Partner Violence Diagnoses | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.85  | Stress Goals SNOMED CT | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.86  | Stress Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.87  | Stress Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.88  | Social Connection Goals SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.89  | Social Connection Goals | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.9  | Food Insecurity Interventions HCPCS | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.90  | Veteran Status Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.91  | Veteran Status Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.92  | Stress Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.93  | Social Connection Interventions SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.94  | Social Connection Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.95  | Social Connection Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.96  | Intimate Partner Violence Interventions SNOMED CT | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.97  | Intimate Partner Violence Procedures | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.98  | Intimate Partner Violence Service Requests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1247.99  | Intimate Partner Violence Goals SNOMED CT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.105  | Mechanical Ventilation Procedures | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.106  | Mechanical Ventilation | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.107  | Mechanical Ventilation | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.109  | aPTT Tests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.119  | Opioid Antagonist | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.12  | High Risk Diagnosis for AKI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.120  | Opioids | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.124  | Immune Modulators | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.130  | Suicide Attempt | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.134  | Central Nervous System Depressants | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.136  | Leukemia or Lymphoma | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.137  | Liver Disease Moderate to Severe | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.138  | COVID19 | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.139  | COVID 19 | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.14  | Hemolytic Uremic Syndrome (HUS) | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.140  | COVID 19 | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.162  | Obesity | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.163  | Antidepressants | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.164  | Antihypertensives | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.165  | Delirium | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.166  | Dementia | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.167  | Psychosis | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.168  | Delirium or Dementia and Other Psychoses | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.169  | Depression | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.170  | Diuretics | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.171  | Epilepsy | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.172  | Neurologic Movement Disorders | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.173  | Neurologic Disorders, Other | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.174  | Neurologic Movement and Related Disorders | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.175  | Peripheral Neuropathy | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.176  | Stroke | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.177  | Abnormal Weight Loss and Malnutrition | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.178  | Intubation | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.179  | Intubation | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.180  | Tracheostomy Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.181  | Tracheostomy Procedures | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.182  | Head and Neck Surgeries with High Risk Airway Compromise | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.185  | Spinal Surgery | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.187  | Routes of Administration for Opioid Antagonists | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.19  | High Risk Procedures for AKI | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.197  | Hospital Based Dialysis Services | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.198  | Hospital Based Dialysis Services | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.199  | Hospital Based Dialysis Services | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.200  | Nephrectomy | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.201  | Thrombotic Thrombocytopenic Purpura | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.204  | VTE Prophylaxis | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.205  | Moderate Injuries | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.206  | General and Neuraxial Anesthesia | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.207  | General and Neuraxial Anesthesia | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.208  | General and Neuraxial Anesthesia | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.209  | Non Invasive Oxygen Therapy by Nasal Cannula or Mask | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.21  | Creatinine Mass Per Volume | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.210  | Continuous and Bilevel Positive Airway Pressure | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.211  | Continuous and Bilevel Positive Airway Pressure | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.213  | Non Invasive Oxygen Therapy | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.214  | Non Invasive Oxygen Therapy Devices | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.216  | Procedural Hospital Locations | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.217  | ASA physical status class | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.218  | Blood urea nitrogen lab test | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.219  | Hemoglobin lab test | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.22  | Anticoagulants for All Indications | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.220  | Smoking status | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.221  | Albumin lab test | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.222  | Leukocyte count lab test | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.223  | Bilirubin lab test | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.224  | Aspartate transaminase lab test | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.226  | Cardiac Arrest | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.23  | Coagulation Disorders | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.230  | PO Antibacterials | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.231  | Injectable Antifungals | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.238  | Neuromuscular Disorder | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.239  | Neuromuscular Disorder | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.24  | Malignant Bone Disease | active | 2022-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.240  | Degenerative Neurological Disorder | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.241  | Degenerative Neurological Disorder | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.242  | Heart and Lung Transplants | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.243  | Heart and Lung Transplants | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.245  | Lung Resections and Excisions | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.246  | Lung Resections and Excisions | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.247  | Chest Wall Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.248  | Chest Wall Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.249  | Maxillary Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.250  | Maxillary Procedures | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.251  | Head, Neck, and Thoracic Surgeries with High Risk Airway Compromise | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.252  | Anesthesia Requiring Monitored Care | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.253  | Anesthesia Requiring Monitored Care | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.255  | Anesthesia Requiring Monitored Care | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.256  | Osteoporosis | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.260  | Rivaroxaban Anticoagulant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.262  | Fondaparinux Anticoagulant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.263  | Dalteparin Anticoagulant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.264  | Heparin | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.268  | Enoxaparin Anticoagulant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.271  | Undetectable Lab Result Value | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.272  | Undetectable Lab Result Value | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.274  | Dietary Recommendations | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.275  | Bariatric Procedures | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.276  | Telemedicine Services | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.277  | Prostate Cancer Treatment | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.28  | Traumatic Avulsion of Kidney | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.29  | Rapidly Progressive Nephritic Syndrome | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.301  | LDL Cholesterol | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.33  | Obstetrics and VTE Obstetrics | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.34  | Glucose Lab Test Mass Per Volume | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.349  | Tuberculosis for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.350  | Tuberculosis for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.351  | Tuberculosis for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.352  | Androgen Deprivation Therapy for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.353  | Bacillus Calmette Guerin for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.354  | Bladder Cancer for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.355  | Chemotherapy Agents for Advanced Cancer | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.356  | Cystectomy for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.357  | Cystectomy for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.358  | Cystectomy for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.359  | DEXA Bone Density for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.360  | Hospital Services for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.361  | Immunocompromised Conditions | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.362  | Immunocompromised Conditions | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.363  | Immunocompromised Conditions | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.364  | Immunosuppressive Drugs for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.365  | Mixed Histology Urothelial Cell Carcinoma for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.366  | Morbid Obesity | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.367  | Morbid Obesity | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.368  | Morbid Obesity | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.369  | Unavailability of Bacillus Calmette Guerin for Urology Care | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.370  | Urinary Retention | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.371  | Urinary Retention | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.372  | Urinary Retention | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.374  | Face to Face Interaction | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.375  | Face to Face Interaction | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.376  | HIV Viral Load Tests | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.377  | HIV Viral Load Tests | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.389  | Syphilis Tests | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.4  | Nephrectomy | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.79  | Acute Brain or Spinal Injury or Hemorrhage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.8  | Large Body Surface Area (BSA) Burns | active | 2022-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.80  | Pulmonary Arterial Thrombectomy | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.81  | Extracorporeal Membrane Oxygenation | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.85  | Elective Inpatient Encounter | active | 2023-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.86  | Intubation | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.88  | Acute Respiratory Failure | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.89  | Tracheostomy Diagnoses | active | 2022-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.90  | Tracheostomy Procedures | active | 2023-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.91  | Neuromuscular Disorder | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.92  | Degenerative Neurological Disorder | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.93  | Head and Neck Surgeries with High Risk Airway Compromise | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.94  | Oxygen Partial Pressure in Arterial Blood | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.95  | Carbon Dioxide Partial Pressure in Arterial Blood | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1248.96  | Arterial Blood pH | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.2  | Psychological Neuropsychological or Neurobehavioral Testing | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1250.3  | Psychological or Neuropsychological Testing | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.10  | Tricuspid Valve Regurgitation | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.12  | Hypertension | active | 2022-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.2  | Valvular Heart Disease | active | 2022-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.22  | Acute Kidney Injury | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.23  | Anemia | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.24  | Cardiac Arrhythmias | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.25  | Attention Deficit and Hyperactivity Disorder | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.26  | Cerebrovascular Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.27  | Seizure Disorder | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.28  | Proteinuria | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.29  | Thyroid Hormone Disorder | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.30  | Thromboembolic Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.31  | Parkinson's Disease and Parkinsonism | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.32  | Upper GI Diseases | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.33  | Failure to Thrive | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.34  | Osteoporosis | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.35  | Mood Disorders | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.36  | Dyslipidemia | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.37  | Heart Failure | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.38  | Coronary Artery Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.39  | Chronic Kidney Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.40  | Chronic Obstructive Pulmonary Disease | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1251.41  | Diabetes Mellitus | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.1  | EventTiming-TimingEvent | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1254.2  | EventTiming-EventTiming | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.1  | Gonorrhea Screening | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1258.2  | Abnormal Weight Loss | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.2  | Prescribable brand and generic non insulin drugs for hyperglycemia in Type 2 Diabetes | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.3  | Prescribable brand and generic insulins and analogues | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.4  | eGFR Using 2021 Race Free Formulas | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.5  | Fructosamine in Serum or Plasma | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.6  | Glucose tests in venous blood, capillary blood, serum/plasma for Diabetes | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.7  | Creatinine in serum/plasma | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1259.9  | IgE Agonists, prescribable | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.10  | Estrogen Receptor Testing for Orserdu | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.100  | MMR Proficient | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.101  | Systemic Cancer Directed Therapy | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.102  | Face To Face Interaction | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.104  | Erdafitinib | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.107  | Chemotherapy Encounter | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.108  | Urothelial Cancers ICD9 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.109  | Urothelial Cancer ICD10 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.11  | Estrogen Receptor Test for Orserdu | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.110  | Urothelial Cancers | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.111  | Prior Therapies for Erdafitinib | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.112  | Urothelial Cancer Histologies | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.113  | Malignant Tumor Behavior | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.114  | Localized Bladder Cancer Stage SNOMED | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.116  | Localized Bladder Cancer Staging | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.117  | Advanced Bladder Cancer Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.118  | Localized Bladder Cancer T Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.119  | Localized Bladder Cancer T Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.12  | Negative | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.120  | Localized Bladder Cancer N Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.121  | Localized Bladder Cancer M Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.122  | Advanced Bladder Cancer M Stage | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.124  | Locoregional Urothelial Cancer ICD9 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.125  | Locoregional Urothelial Cancer ICD10 | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.126  | Locoregional Urothelial Cancer SNOMED | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.127  | Locoregional Urothelial Cancer | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.128  | FGFR3 Gene | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.129  | FGFR3 Gene Interpretation Positive SNOMED | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.13  | HER2 Negative | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.130  | FGFR3 Gene Interpretation Positive LOINC | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.131  | FGFR3 Gene Interpretation Positive NCI | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.133  | FGFR3 Gene Interpretation Positive | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.134  | FGFR3 Gene Interpretation Negative SNOMED | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.135  | FGFR3 Gene Interpretation Negative NCI | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.137  | FGFR3 Gene Interpretation Negative | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.138  | FGFR3 Molecular Variants | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.139  | Tumor Behavior | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.14  | Endocrine Therapy | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.140  | Physcological Support for Cancer | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.141  | Referral For Pain From Cancer | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.142  | Cancer Pain Education | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.143  | Telehealth Encounters | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.144  | Pain Assessment Score | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.146  | Telehealth Encounters SNOMEDCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.147  | Telehealth Encounters CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.148  | Telehealth Encounters HCPCS | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.149  | Telehealth Encounters All | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.15  | All Metastatic Sites | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.150  | Chemo Admin SNOMEDCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.151  | Chemo Admin CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.152  | Chemo Admin HCPCS | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.153  | Chemotherapy Administration All | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.154  | Radiation Treatment CPT | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.155  | Radiation Treatment HCPCS | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.156  | Radiation Treatment SNOMEDCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.157  | Radiation Treatment All | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.158  | Bipolar Diagnosis Codes | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.159  | Telephone Visits SNOMED | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.16  | All Metastatic Sites | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.160  | Telephone Visit CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.161  | Telephone Visits All | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.162  | Adolescent depression screening assessment | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.163  | Adult depression screening assessment LOINC | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.165  | Referral for Depression Adult | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.166  | Referrals for Adolescent Depression | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.167  | Follow Ups for Adolescent Depression | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.168  | FollowUps for Adult Depression | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.169  | Depression Screen Declined for Medical Reason | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.17  | Metastatic Breast Cancer | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.170  | Physical Therapy Evaluations SNOMEDCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.171  | Physical Therapy Evaluation CPT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.172  | Physical Therapies Evaluations | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.173  | Non Opioid Analgesics | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.174  | Adjuvant Analgesics | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.176  | Lung Cancer ICD9 | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.177  | Lung Cancer ICD10 | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.178  | Lung Cancer | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.179  | Prior Therapies for Osimertinib | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.18  | Stage IA | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.181  | Plan of Care for Pain | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.182  | All Antineoplastic Agents | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.183  | Locally Advanced NSCLC Stage Group | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.185  | Localized NSCLC Stage Group SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.186  | Radiation Treatment Management | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.187  | Plan of Care | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.188  | Documentation of Plan of Care | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.189  | Pain Present | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.19  | Stage IB | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.190  | Localized NSCLC Stage Group NCIM | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.192  | Localized NSCLC Stage Group | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.193  | Advanced NSCLC Stage Group | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.194  | NSCLC M Stage (metastatic) | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.195  | NSCLC T Stage | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.196  | NSCLC N Stage | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.197  | SCLC and rarer lung cancer histology | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.198  | EGFR Gene | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.199  | EGFR Gene Interpretation Positive SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.20  | Stage IIA | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.200  | EGFR Gene Interpretation Positive LOINC | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.201  | EGFR Gene Interpretation Positive | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.202  | EGFR Osimertinib Molecular Variants | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.203  | EGFR Generic Molecular Variant NCIM | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.204  | EGFR Generic Molecular Variant SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.205  | EGFR Generic Molecular Variant LOINC | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.206  | EGFR Molecular Variants Osimertinib PM | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.207  | Osimertinib | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.208  | Pemetrexed | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.209  | Radiation Treatment Management SNOMEDCT | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.21  | Stage IIB | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.210  | Radiation Treatment Management Codes | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.211  | Radiation Treatment Delivery CPT | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.212  | 77427 Management Code | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.213  | Radiation Treatment Delivery HCPCS | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.214  | Radiation Treatment Delivery NCIM | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.215  | Radiation Treatment Delivery SNOMED | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.216  | Radiation Treatment Delivery | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.217  | MET Gene Test | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.219  | Tepotinib | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.22  | Stage IIIA | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.220  | MET Positive gene interpretation | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.227  | MET Exon 14 skipping molecular variant | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.23  | Stage IIIB | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.230  | All Cancer Directed therapies | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.231  | EGFR Amivantamab Molecular Variants | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.232  | EGFR Molecular Variants Amivantamab PM | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.233  | test43 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.234  | ROS1 Molecular Variants Repotrectinib PM | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.235  | ROS1 Repotrectinib Molecular Variants | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.236  | ROS1 Negative (geneinterpretation) SNOMEDCT | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.237  | ROS1 Negative (geneinterpretation) NCI | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.238  | ROS1 Negative (geneinterpretation) SNOMEDCT,NCI | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.239  | ROS1 Positive (geneinterpretation) | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.24  | Stage IIIC | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.240  | ROS1 results (HGNC) | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.241  | ROS1 Gene Rearrangement | active | 2024-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.242  | RET Test (HGNC) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.243  | RET Positive (Genei interpretation ) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.244  | RET Gene Rearrangement | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.245  | RET Negative (geneinterpretaion) SNOMED | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.246  | RET Negative (geneinterpretaion) NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.247  | RET Negative (geneinterpretaion) SNOMEDCT,NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.248  | RET Fusion Molecular Variants | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.249  | pralsetinib | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.25  | ESR1 Gene Test | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.250  | Repotrectinib Value set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.251  | Amivantamab | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.252  | Alectinib Drug | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.253  | Gemcitabine Drug Value set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.254  | vinorelbine Drug | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.255  | NSCLC_Tumor_resection SNOMEDCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.256  | NSCLC_Tumor_resection CPT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.257  | NSCLC_Tumor_resection SNOMEDCT CPT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.258  | ALK results (HGNC) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.259  | ALK Positive (geneinterpretation) SNOMED | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.26  | ESR1 Genetic Mutation | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.260  | ALK Positive (geneinterpretation) NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.261  | ALK Positive (geneinterpretation) SNOMEDCT NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.262  | ALK Negative (geneinterpretation) SNOMEDCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.263  | ALK Negative (geneinterpretation) NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.264  | ALK Negative (geneinterpretation) SNOMEDCT NCI | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.265  | Locoregional Sites | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.266  | NSCLC N2 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.267  | NSCLC N1 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.268  | NSCLC N0 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.269  | NSCLC T3_T4 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.27  | Genetic Test Finding | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.270  | NSCLC T2 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.271  | NSCLC T1 Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.272  | Locally_Advanced_Metastatic_NSCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.273  | Localized_Inclusion_NSCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.274  | Localized_Exclusion_NSCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.275  | tarlatamab dlle | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.276  | Extensive SCLC Stage Group SNOMEDCT | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.277  | Extensive SCLC Stage Group NCIM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.278  | Extensive SCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.279  | Localized SCLC Stage Group | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.28  | Her2 Negative | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.280  | SCLC M Stage (metastatic) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.281  | SCLC T Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.282  | SCLC N Stage | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.283  | SCLC histology (to include those patients) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.284  | Binimetinib | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.285  | Encorafenib | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.286  | Encorafenib PM Molecular variant | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.288  | BRAF Positive (geneinterpretation) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.289  | BRAF test (HGNC) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.29  | HER2 Positive | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.292  | Prior therapy for Amivantamab | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.293  | ENHERTU Drug | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.294  | Metastatic_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.295  | Locally_Advanced_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.296  | Localized_Solid_Cancer_Stage Group SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.297  | Solid cancer M Stage (metastatic) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.298  | Solid Cancer T Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.299  | Solid Cancer N Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.30  | HER2 Positive | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.302  | HER2_IHC_Positive | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.303  | HER2 Negative (geneinterpretation/Labtestvalue) SNOMED | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.304  | HER2 Negative (geneinterpretation/Labtestvalue) LOINC | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.305  | HER2 Negative (geneinterpretation/Labtestvalue) NCI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.307  | HER2 Negative (geneinterpretation/Labtestvalue) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.308  | Solid Cancer Diagnosis ICD 9 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.309  | Solid Cancer Diagnosis SNOMED CT | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.31  | HER2 Positive | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.310  | Solid Cancer Diagnosis | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.311  | Localized_Solid_Cancer_Stage Group NCIM | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.313  | Localized_Solid_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.314  | Locally_Advanced_Solid_Cancer_Stage Group NCIM | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.315  | Locally_Advanced_Solid_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.316  | Metastatic_Solid_Cancer_Stage Group NCIM | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.317  | Metastatic_Solid_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.318  | Solid Cancer T Stage LOINC | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.319  | Solid Cancer T Stage NCI | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.32  | HER2 Positive | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.320  | Solid Cancer T Stage codes | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.321  | Prior_Systemic_therapy_Enhertu | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.322  | RET test_Solid_cancer (HGNC) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.323  | RET Positive_Solid_Cancer (geneinterpretation) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.324  | RET Negative_Solid_Cancer (geneinterpretation) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.325  | RET fusion Molecular Variants_Solid_Cancer | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.326  | Prior_systemic_therapy_Retevmo | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.327  | Selpercatinib (Retevmo) Drug | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.328  | Breast Cancer Diagnosis ICD9 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.329  | Breast Cancer Diagnosis ICD10 | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.33  | Metastatic Breast Cancer | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.330  | Breast Cancer Diagnosis | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.331  | Metastatic_Breast_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.332  | Locally_Advanced_Breast_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.333  | Localized_Breast_Cancer_Stage Group | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.334  | Breast cancer M Stage (metastatic) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.335  | Breast Cancer T Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.336  | Breast Cancer N Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.337  | Metastatic Sites All Breast SNOMEDCT | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.338  | Metastatic Sites All Breast ICD9 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.339  | Metastatic Sites All Breast ICD10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.340  | Metastatic Sites All Breast (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.341  | Aromatase_Inhibitor therapy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.342  | Capivasertib_therapy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.343  | Fulvestrant_therapy | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.344  | PTEN_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.345  | PTEN_geneinterpretation | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.346  | PIK3CA_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.347  | PI3KCA_geneinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.348  | AKTI_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.349  | AKTI_geneinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.35  | All Metastatic Sites | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.350  | Progesterone_receptor_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.351  | Progesterone_receptor_geneinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.352  | Estrogen_receptor_gene | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.353  | Estrogen_receptor_geneinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.354  | Progesterone_receptor_labtest | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.355  | Progesterone_receptor_labinterpretation | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.356  | Estrogen_receptor_labtest | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.357  | Estrogen_receptor_labinterpretation | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.358  | NSCLC M0 Stage | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.359  | HER2_IHC_test_Gene | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.36  | All Metastatic Sites | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.360  | HER2_IHC_test_Lab | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.361  | HER2_Fish_test | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.362  | HER2_IHC_Negative | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.363  | Trodelvy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.364  | Chemotherapy_breast_cancer | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.365  | Cyclin_dependent_kinase | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.366  | Taxane_Trodelvy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.367  | Endocrine_therapy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.368  | HER2_Fish_test_Negative | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.369  | HER2_IHC_Equivocal | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.37  | Locoregional Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.370  | HER2 Positive_PM_results | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.371  | HER2 test_Lab | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.372  | HER2 test_gene | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.374  | Thyroid Cancer Diagnosis | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.375  | Metastatic_Thyroid_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.376  | RET mutation_Molecular Variants | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.377  | RET Gene mutation | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.378  | Locally_Advanced_Localized_Thyroid_Cancer_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.379  | Thyroid cancer M1_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.38  | Locoregional Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.380  | Thyroid_cancer_M0_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.381  | Thyroid_cancer_T_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.382  | Thyroid_cancer_T1_T2_T3_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.383  | Thyroid_cancer_T4_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.384  | Thyroid_cancer_N1b_Stage&Above | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.385  | Thyroid_cancer_N_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.386  | Medullary_thyroid_histology | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.387  | RET test_Thyroid_cancer (HGNC) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.388  | RET Positive | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.389  | NSCLC N3 Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.39  | Locoregional Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.390  | CRC Cancer Diagnosis ICD9 | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.391  | CRC Cancer Diagnosis ICD10 | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.392  | CRC Cancer Diagnosis ICD9/ICD10 | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.393  | Metastatic_CRC_Cancer_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.394  | Locally_Advanced_Localized_CRC_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.395  | CRC cancer M Stage (metastatic) | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.396  | CRC Cancer T Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.397  | CRC Cancer N Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.398  | KRAS_gene | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.399  | KRAS_negative | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.40  | Locoregional Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.400  | Fluoropyrimidine_CRC | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.401  | Oxaliplatin | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.402  | Irinotecan_based_therapy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.403  | anti_VEGF_therapy_CRC | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.404  | anti_EGFR_therapy_CRC | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.405  | fruquitinib | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.406  | Locally_Advanced_CRC_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.407  | Localized_CRC_Stage Group | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.408  | CRC cancer M0_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.409  | CRC_Cancer_T1_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.41  | All Metastatic Sites ICD910 | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.410  | CRC_Cancer_T2_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.411  | CRC_Cancer_T3_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.412  | CRC_Cancer_T4_Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.413  | CRC Cancer N1 Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.414  | CRC Cancer N2 Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.415  | CRC Cancer N2b Stage | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.416  | KRAS_G12C_MV | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.417  | KRAS_G12C_PM | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.418  | KRAS_positive | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.419  | Adagrasib | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.42  | Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.420  | cetuximab_therapy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.421  | Tamoxifen_therapy | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.423  | Endometrial Cancer Diagnosis ICD 10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.425  | Endometrial Cancer Diagnosis ICD9CM | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.426  | Endometrial Cancer Diagnosis | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.428  | Localized_Endometerial_Stage Group SNOMED | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.429  | Localized_Endometerial_Stage Group NCIM | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.43  | Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.431  | Endometrial_Sarcoma_Tumor_Histology_exc | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.432  | Endometrial cancer M Stage (metastatic) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.433  | Endometrial_M0_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.436  | Prior_therapy_Endometrial | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.437  | Paclitaxel_therapy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.44  | Breast Cancer | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.441  | Carboplatin_therapy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.442  | Durvalumab_therapy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.444  | MMR_Gene_Lab_LOINC | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.447  | MMR_Gene_HGNC | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.449  | Endometrial_ Cancer N Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.45  | Endometrial Cancer ICD9 | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.451  | Endometrial_N0_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.453  | Endometrial_N1_N2_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.455  | Endometrial_T1_T3_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.456  | Endometrial_T3_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.458  | Endometrial_T4_Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.459  | Endometrial Cancer T Stage | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.46  | Endometrial Cancer ICD10 | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.460  | Localized_Endometerial_Stage Group_SNOMED/NCIM | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.461  | Metastatic Sites All CRC | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.462  | Metastatic Sites All CRC ICD 10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.463  | Metastatic Sites All CRC ICD 9 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.464  | Metastatic Sites All CRC (grouped, SNOMEDCT/ICD9/ICD10) | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.465  | NTRK Repotrectinib Molecular Variants | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.466  | NTRK_Gene_rearrangment | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.467  | Prior_Systemic_therapy_Repotrectinib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.468  | NTRK_Positive | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.469  | NTRK_test_gene | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.47  | Systemic treatment for endometrial cancer | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.470  | Tamoxifen_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.471  | Toremifene_trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.472  | Fulvestrant_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.473  | Elacestrant | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.474  | Anastrozole_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.475  | Leuprolide_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.476  | Abemaciclib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.477  | Palbociclib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.478  | Ribociclib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.479  | Carboplatin_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.48  | Endometrial Cancers | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.480  | Cisplatin_Trodelvy | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.481  | Cyclophosphamide | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.482  | Methotrexate | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.483  | Gemcitabine | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.484  | Capecitabine | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.485  | Eribulin | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.486  | Doxorubicin | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.487  | Vinorelbine | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.488  | Epirubicin | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.489  | Ixabepilone | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.49  | MSI Testing | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.490  | Olaparib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.491  | Talazoparib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.492  | Entrectinib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.493  | larotrectinib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.494  | Alpelisib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.495  | Capivasertib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.496  | Pembrolizumab | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.497  | Dostarlimab | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.498  | Selpercatinib | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.499  | Everolimus | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.50  | MSI High | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.500  | Trastuzumab_deruxtecan | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.501  | Test 23 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.502  | All Metastatic sites Endometrial SNOMED | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.503  | All Metastatic sites Endometrial ICD9 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.504  | All Metastatic sites Endometrial ICD10 | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.505  | All Metastatic sites Endometrial | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.506  | Create CRC_Cancer_T4a_Stage | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.507  | Create CRC_Cancer_T4b_Stage | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.508  | High Emetogenic Risk Chemotherapy | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.510  | InactiveFollowup | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.53  | MMR Gene Testing | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.54  | MSI High | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.55  | MSI High | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.56  | Early and Limited Stage | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.57  | Early Stage IIB or lower | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.58  | MMR Deficient | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.59  | MMR Deficient | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.6  | Orserdu | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.60  | MMR Deficient | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.61  | Stage IIB or lower and limited | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.62  | Stage III or higher | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.63  | Stage III or higher | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.64  | Stage III or higher | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.65  | Staging Unknown | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.66  | Staging Unknown | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.67  | Staging Unknown | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.68  | Jemperli | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.69  | Uterine Sarcoma | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.7  | Her2 Test For Orserdu | active | 2023-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.70  | Tumor Histology | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.71  | Platinum based therapy | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.72  | Prior Therapies for Tucatinib | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.73  | Tucatinib | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.74  | Colorectal Cancer ICD10 | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.75  | Colorectal Cancer ICD9 | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.76  | Colorectal Cancer ICD9 and ICD10 | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.78  | Advanced or Unresectable Colorectal Cancer Staging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.79  | 0 to IIIB Colorectal Cancer Staging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.80  | Colorectal Cancer M1 Stage | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.81  | RAS Genes | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.82  | RAS Gene Interpretation Negative LOINC | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.83  | RAS Gene Interpretation Negative SNOMED | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.84  | RAS Gene Interpretation Negative NCM | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.85  | RAS Gene Negative | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.86  | RAS Gene Interpretation Positive SNOMED | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.87  | RAS Gene Interpretation Positive LOINC | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.88  | RAS Gene Positive | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.89  | Her2 Testing | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.9  | ER Test for Orserdu | active | 2023-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.90  | Patient Reason | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.91  | MSI High NCI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.92  | MSI Low SNOMED | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.93  | MSI Low LOINC | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.94  | MSI Low NCI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.95  | MSI Low | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.96  | MMR Deficient NCI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.97  | MMR Proficient SNOMED | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.98  | MMR Proficient LOINC | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1260.99  | MMR Proficient NCI | active | 2024-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1262.3  | ICD9 Codes for HIV Diagnosis | active | 2023-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.1  | Inpatient Pneumonia Diagnosis | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.11  | Chest Imaging for Pneumonia, HCPCS | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.12  | Chest Imaging for Pneumonia Grouping Definition | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.18  | ICD9 Abnormal Finding on Chest Imaging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.19  | ICD10 Abnormal Finding on Chest Imaging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.2  | ICD9 Pneumonia Definition | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.20  | SNOMEDCT Abnormal Finding on Chest Imaging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.21  | Abnormal Finding on Chest Imaging | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.22  | SNOMEDCT Pneumonia Definition | active | 2023-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.23  | CAP Concurrent Infections | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.24  | CAP Pneumonia Diagnostic | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.25  | Antibiotic Usage for CAP Diagnosis | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.27  | Legionella Presence by Urine Antigen or DNA | active | 2024-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.29  | Broad Spectrum Antibiotics for MDRO | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.3  | ICD10 Pneumonia Definition | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.32  | CPT Transplants, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.33  | HCPCS Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.34  | ICD10CM Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.35  | ICD10PCS Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.37  | SNOMEDCT Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.38  | Transplant, Stem Cell and Solid | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.39  | Antibiotic Usage for CAP Duration | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.40  | CAP Sepsis Diagnostic | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.41  | CAP Respiratory Failure Diagnostic | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.42  | MRSA Organism or Substance in Lab Results | active | 2024-12 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.8  | Systemic Antimicrobials | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1264.9  | Chest Imaging for Pneumonia, CPT | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.1  | Problem Type | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.10  | Information Source for Medication Adherence HSLOC | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.11  | Information Source for Medication Adherence | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.13  | Screening and Assessment Survey Codes | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.14  | Unknown and Asked but Unknown (DAR) | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.15  | Yes or No SCT | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.16  | Answer Set with Yes No and Unknowns | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.17  | Common LOINC Lab Codes | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.18  | Radiology Procedures (LOINC) | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.19  | Clinical Tests | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.21  | Universal Common LOINC Lab Orders | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.22  | Route of Administration of Therapeutic Agents | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.23  | Encounter Type | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.24  | Specimen Condition SCT | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.25  | Detailed race including absence reasons. | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.26  | Healthcare Facility type (SCT) | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.27  | Social History Type (LOINC) | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.28  | Social History Type | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.29  | Encounter Type CPT | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.3  | Smoking status comprehensive | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.31  | Healthcare Service Location Type Combined | active | 2025-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.4  | Smoking Status Type LOINC | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.5  | Smoking Status Pack Years SCT | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.6  | Smoking Status Type | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.7  | Information Source for Medication Adherence HL7 Role Code | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.8  | Information Source for Medication Adherence ParticpationFunction | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1267.9  | Information Source for Medication Adherence SCT | active | 2024-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.1  | Malnutrition | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.10  | Fracture | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.11  | Transplant Diagnoses | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.13  | Transplant Diagnoses ICD10CM | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.14  | Transplant Diagnoses SNOMED CT | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.15  | Respiratory Procedures | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.2  | Moderate Injuries (SNOMEDCT) | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.3  | Diabetes | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.4  | Diabetes | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.5  | Diabetes | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.6  | Immobility | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.7  | Smoking status | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.8  | Obesity | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1272.9  | Hormone Therapy | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.1  | Drug Intervention Not Indicated/Contraindicated | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.10  | Endotracheal Intubation | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.2  | Procedure Not Indicated/Contraindicated | active | 2024-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1282.9  | Mechanical Circulatory Assist Device | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.1  | RXNormSBD0305 | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1289.2  | RXNormSCD0305 | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.4  | Sequential Organ Failure Assessment SOFA | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.5  | Septic Shock | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1290.6  | Septic Shock | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.1  | Administrative Gender (HL7 V3) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10267  | ParticipationFunction | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10416  | Financially Responsible Party Type Value Set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10612  | Unknown Null | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10637  | PostalAddressUse | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.10901  | ParticipationType | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.11610  | x_ActRelationshipDocument | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12199  | LanguageAbilityProficiency | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12212  | Marital Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.12249  | LanguageAbilityMode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.14914  | Race Value Set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.15913  | EntityNameUse | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.16926  | HL7 BasicConfidentialityKind | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.18877  | Coverage Role Type Value Set | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19185  | Religious Affiliation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19563  | Personal Relationship Role Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19579  | Family Member Value | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19601  | x_ServiceEventPerformer | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.19717  | No Immunization Reason | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.12  | HealthStatus | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.3  | ReferralDocumentType | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.4  | TransferDocumentType | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.5  | Wound Measurements | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.6  | Wound Type | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.7  | Nutritional Status | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2.9  | Nutrition Recommendations | active | 2018-05 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.2  | Advance Directive Type Code | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20.22  | HPDocumentType | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20275  | HealthcareServiceLocation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.20549  | Criticality Observation | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.1.11.78  | Observation Interpretation (HL7) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.1  | Initial Case Report Trigger Code Result Status | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.15.2.5.12  | Therapeutic Response to Medication | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.300  | Transmission Based Precaution Types | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.304  | Organism | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.305  | Microbiology and Antimicrobial Susceptibility Tests | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.22.5.306  | Infectious Disease | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.2  | Codes for MDRO and CDI Summary Data LTCF | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.3  | NHSNPrimaryResidentServiceType | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.4  | Codes for Denominators for Long Term Care Locations LTCF | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.5.9.5  | Codes for Prevention Process Measures LTCF | active | 2023-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.1.9.1  | NHSNReportNoEventsMDROLTCF | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.10  | Codes for Healthcare Personnel Influenza Vaccination (HP FLU) Summary Data | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.11  | Codes for Hemovigilance (HV) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.12  | Codes for Intensive Care Unit (ICU) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.13  | Codes for Neonatal Intensive Care Unit (NICU) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.15  | Codes for Prevention Process and Outcome Measures (POM) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.16  | Codes for Specialty Care Area (SCA) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.17  | Codes for Vascular Access Type (Dialysis) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.18  | NHSNReportNoEventsICU | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.19  | NHSNReportNoEventsNICU | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.20  | NHSNReportNoEventsSCA | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.21  | NHSNReportNoEventsMDRO | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.22  | NHSNReportNoEventsDialysis | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.24  | NHSNVascularSpecimenCollectionSite | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.29  | NHSNSSIDetectionMethod | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.3  | NHSNLastLocationEncounterTypeCode | active | 2020-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.30  | NHSNLOS/MENDischargeDisposition | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.31  | NHSNSSIDetectionMethodType | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.32  | Codes for Outpatient Procedure Component Same Day Outcome Measures Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.33  | NHSNReportNoEventsOPCSameDayOutcomeMeasures | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.34  | NHSNOPCProcedureCategoryCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.35  | NHSNReportNoEventsAR | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.4  | NHSNDrugSusceptibilityTestMethod | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.40  | NHSN COVID19 Case Classification | active | 2021-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.5  | NHSN Pathogen Reduced Apheresis Platelet Usage | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.50  | NHSNGenotypicTestInterpretation | active | 2024-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.6  | HealthcarePersonnelType | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.7  | NHSNInfluenzaVaccinationSetting | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.8  | Codes for Antimicrobial Resistance Option (ARO) Summary Data | active | 2020-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.10.20.5.9.9  | Codes for Antimicrobial Usage, Pharmacy (AUP) Summary Data | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.1.1  | SurgicalOperationNoteDocumentTypeCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.12.1  | Personal And Legal Relationship Role Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.4.1  | DischargeSummaryDocumentTypeCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.6.1  | ProcedureNoteDocumentTypeCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.7.1  | SupportedFileFormats | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.8.1  | ProgressNoteDocumentTypeCode | active | 2024-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.18  | MoodCodeEvnInt | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.19  | ProblemAct statusCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.20  | Telecom Use (US Realm Header) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.21  | AgePQ_UCUM | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.22  | ProcedureAct statusCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.23  | Planned moodCode (Act/Encounter/Procedure) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.24  | Planned moodCode (SubstanceAdministration/Supply) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.25  | Planned moodCode (Observation) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.26  | EntityPersonNamePartQualifier | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.29  | DIRQuantityMeasurementTypeCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.31  | ConsultDocumentType | active | 2025-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.32  | DIRDocumentTypeCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.33  | INDRoleclassCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.34  | Patient Education | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.35  | Pressure Ulcer Stage | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.36  | Pressure Point | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.37  | TargetSite Qualifiers | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.38  | Smoking Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.39  | Result Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.41  | Tobacco Use | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.44  | Mental and Functional Status Response | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.46  | Ability | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.47  | ADL Result Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.49  | Residence and Accommodation Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.50  | Sensory Status Problem Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.51  | Healthcare Agent Qualifier | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.52  | Encounter SCT | active | 2024-10 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.54  | Planned Intervention moodCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.55  | Goal Achievement | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.56  | Referral Types | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.58  | Wound Characteristic | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.59  | DIRSectionTypeCodes | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.60  | Priority Level | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.61  | Care Model | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.62  | Related Document (append/replace) | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.65  | Physical Exam Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.66  | Patient Referral Act moodCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.68  | Note Types | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.1  | Advance Care Planning Services CPT | active | 2018-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.2  | Advance Care Planning Services SCT | active | 2018-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.1.3  | Advance Care Planning Services Grouping | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.17  | Obligation or Prohibition Instruction Type | active | 2018-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.4  | Advance Healthcare Directive Categories LOINC | active | 2025-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.5  | Advance Directives Content Types | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.6  | Planned or Completed moodCode | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.69.7  | Obligation or Prohibition Instruction Type | active | 2017-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.80  | Pregnancy Status Determination Method | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.81  | Estimated Date of Delivery Including Method | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.82  | Estimated Gestational Age Code Including Method | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.84  | Other Pregnancy Outcome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.86  | Pregnancy Outcome | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.87  | Postpartum Status | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.88  | Pregnancy Related Findings | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.89  | D(Rh) Type | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.90  | D(Rh) Sensitized | active | 2024-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.11.20.9.91  | Rho(D) Immune Globulin | active | 2023-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.1  | NHSNEncounterTypeCode | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.10  | NHSNASAClassCode | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.11  | NHSNSpinalFusionLevelCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.12  | NHSNOccasionOfDetectionCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.13  | NHSNDrugSusceptibilityFindingCode | active | 2020-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.15  | NHSNDrugSusceptibilityTestsCode | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.16  | NHSNPathogenCode | active | 2023-11 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.17  | NHSNProcedureCategoryCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.19  | NHSNHealthcareServiceLocationCode | active | 2019-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.2  | NHSNSpinalFusionApproachCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.20  | NHSNInfectionTypeCode | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.3  | NHSNHipReplacementCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.4  | NHSNKneeReplacementCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.6  | NHSNInfectionRiskFactorsCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.7  | NHSNBloodStreamInfectionEvidenceTypeCode | active | 2020-08 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.13.9  | NHSNWoundClassCode | active | 2020-07 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.17.4077.2.1017  | Closed Head and Facial Trauma | active | 2020-09 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.17.4077.2.1018  | Closed Head and Facial Trauma | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.1  | Major Surgical Procedure | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.134  | Oral Factor Xa Inhibitor for VTE Prophylaxis or VTE Treatment | active | 2022-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.136  | Perforation of Uterus | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.137  | Uterine Window | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.138  | Uterine Rupture | active | 2024-04 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.200  | Anticoagulant Therapy | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.201  | Antithrombotic Therapy Anticoagulant | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.202  | Atrial Fibrillation or Flutter | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.203  | Atrial Ablation | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.204  | Carotid Intervention | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.205  | Direct Thrombin Inhibitor | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.207  | Discharged to Health Care Facility for Hospice Care | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.209  | Discharged to Home for Hospice Care | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.211  | Injectable Factor Xa Inhibitor for VTE Prophylaxis | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.212  | Hemorrhagic Stroke | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.213  | INR | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.214  | Intermittent pneumatic compression devices | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.215  | LDLc | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.218  | Unfractionated Heparin | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.219  | Low Molecular Weight Heparin for VTE Prophylaxis | active | 2023-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.222  | Intravenous route | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.223  | Subcutaneous route | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.226  | Thrombolytic tPA Therapy | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.230  | Venous foot pumps | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.232  | Warfarin | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.234  | Hemorrhagic Stroke | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.235  | Hemorrhagic Stroke | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.238  | Carotid Intervention | active | 2025-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.239  | Carotid Intervention | active | 2019-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.242  | Atrial Ablation | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.243  | Atrial Ablation | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.244  | Atrial Fibrillation or Flutter | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.245  | Atrial Fibrillation or Flutter | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.246  | Atrial Fibrillation or Flutter | active | 2025-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.247  | Ischemic Stroke | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.25  | Single Live Birth | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.251  | Ischemic Stroke Embolism | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.252  | Ischemic Stroke Embolism | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.255  | General Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.256  | Graduated compression stockings | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.257  | Gynecological Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.258  | Hip Fracture Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.259  | Hip Replacement Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.26  | Single Live Born Newborn Born in Hospital | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.260  | Intracranial Neurosurgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.261  | Knee Replacement Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.263  | Obstetrical or Pregnancy Related Conditions | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.264  | Obstetrics VTE | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.27  | Dietary Intake Other than Human Milk | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.270  | Acute or Persistent Asthma | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.271  | Acute or Persistent Asthma | active | 2022-01 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.272  | Urological Surgery | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.279  | Venous Thromboembolism | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.281  | Labor | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.282  | Cesarean Birth | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.286  | Conditions Possibly Justifying Elective Delivery Prior to 39 Weeks Gestation | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.288  | Medical Induction of Labor | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.292  | Emergency Department Visit | active | 2021-06 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.294  | Decision to Admit to Hospital Inpatient | active | 2021-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.295  | Decision to Admit to Hospital Inpatient | active | 2022-03 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.296  | Psychiatric/Mental Health Diagnosis | active | 2024-02 |
us.nlm.vsac | R4 | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.117.1.7.1.298  |